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Non-alcoholic steatohepatitis (NASH) 
is a common cause of chronic liver 
disease. However, pathogenesis of 
NASH is still partly unclear. In this 
thesis, a non-invasive NASH score was 
developed. It estimated population 
prevalence of 5% for NASH in Finnish 
adults. Furthermore, alterations in 
cholesterol metabolism, lipid oxidation 
and ketone body metabolism were 
revealed in those with NASH. This 
thesis highlights the significance of 
NASH and relates it with risk factors 
for other common diseases.
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ABSTRACT: 
 
Obesity and type 2 diabetes are serious global health threats. They associate closely with 
non-alcoholic fatty liver disease (NAFLD). Already 20-30% of individuals worldwide have 
non-alcoholic fatty liver (NAFL), which is the primary phenotype of NAFLD. However, it is 
not known why some people will develop non-alcoholic steatohepatitis (NASH), which can 
further progress to liver cirrhosis. NAFLD increases not only liver-related morbidity and 
mortality, but also cardiovascular diseases and cancers. The real prevalence of NASH is not 
known, since diagnosis of NASH needs a liver biopsy. A non-invasive method would be 
helpful not only for diagnostics, but also in population based studies, where liver biopsies 
cannot be obtained. Attempts have been made to develop different non-invasive diagnostic 
methods. Novel biomarkers could be related to pathogenesis of NASH. For example, 
changes in cholesterol and lipid metabolism have been observed in those with NASH.  
In this thesis, a non-invasive score was developed in a cohort of 296 obese individuals 
with all essential NASH-associated measurements and parameters available. A score 
consisting of PNPLA3 rs738409 genotype, aspartate aminotransferase (AST) and fasting 
insulin found NASH with a sensitivity of 72% and specificity of 74%. Next, the score was 
validated in an Italian population of 380 obese individuals. Finally, in the Finnish D2D 
population study the score estimated the prevalence of 5% for NASH in Finnish adult 
individuals, when used. Cytokeratin 18 (CK-18) has been stated to be the best biomarker for 
NASH. CK-18 found NASH rather well also in this study, but it did not improve the 
predictive value of the score. The potential of CK-18 as a marker of intervention effect in the 
liver was further tested in HEPFAT dietary intervention study. The value of CK-18 in 
predicting the effect of intervention in the liver was modest. 
Different lipid subclasses in lipoproteins and low molecular weight molecules were 
measured with nuclear magnetic resonance (NMR) spectroscopy in a population of 116 
massively obese individuals. Total cholesterol concentration of large, medium and small 
VLDL, and large and medium LDL was associated with liver inflammation independently 
of steatosis. Ketone bodies were lower in those with NASH than in those with fatty liver. 
This suggests lower lipid oxidation and decreased mitochondrial function in those with 
NASH. 
The non-invasive score formed in this thesis could be used as a screening method of 
NASH together with serum CK-18 measurement. Awareness of the prevalence of NASH 
should put more focus on prevention and treatment of NAFLD in Finland. The association 
of cholesterol metabolism with NASH suggests that cholesterol metabolism should be the 
target of treatment in NASH. Finally, decreased lipid oxidation and increased ketolysis in 
those with NASH were observed. In summary, this thesis indicates that common NASH is 
associated with multiple alterations in lipid metabolism. 
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TIIVISTELMÄ:  
 
Lihavuus ja tyypin 2 diabetes ovat suuria terveysongelmia maailmanlaajuisesti. Niillä on 
läheinen yhteys ei-alkoholiperäiseen rasvamaksatautiin (NAFLD). Jopa 20-30 %:lla 
väestöstä on ei-alkoholiperäinen rasvamaksa (NAFL), joka on tautikirjon pääasiallinen 
esiintymismuoto. On epäselvää, miksi osalla tämä tauti etenee ei-alkoholiperäiseksi 
maksatulehdukseksi (NASH), joka voi johtaa jopa maksakirroosiin. NAFLD lisää 
maksaperäistä sairastavuutta ja kuolleisuutta, mutta myös sydän- ja verenkiertoelimistön 
sairauksia ja syöpiä. NASH:n todellista esiintyvyyttä ei tiedetä, koska sen diagnosointiin 
vaaditaan maksakoepalan otto. Ei-kajoava diagnostinen menetelmä auttaisi paitsi taudin 
toteamisessa, myös väestötutkimuksissa, joissa maksakoepaloja ei voida ottaa. Tämän takia 
on kehitetty erilaisia ei-kajoavia diagnoosikeinoja. NASH:n uusia merkkiaineita voisi löytyä 
taudin patogeneesia tutkimalla. Esimerkiksi kolesteroli- ja rasva-aineenvaihdunnan 
muutosten ajatellaan liittyvän NASH:n kehittymiseen. 
Tässä väitöskirjatyössä muodostettiin NASH:a ennustava yhtälö 296 lihavan henkilön 
kohortissa, jossa olennaiset NASH:iin liittyvät määritykset olivat saatavilla. Yhtälö koostui 
PNPLA3 rs738409 genotyypistä, aspartaattiaminotransferaasista (ASAT) ja 
paastoinsuliinipitoisuudesta ja löysi NASH:n 72 % herkkyydellä ja 74 % tarkkuudella. 
Yhtälö toimi yhtä hyvin 380 italialaisen kohortissa. Yhtälön avulla arvioitiin NASH:n 
esiintyvyydeksi suomalaisilla aikuisilla n. 5 % D2D-väestötutkimuksessa. Sytokeratiini-18 
(CK-18) ei lisännyt yhtälön tarkkuutta, vaikka se on arvioitu parhaaksi NASH-
merkkiaineeksi. CK-18:n hyötyä interventioiden maksavaikutuksen merkkiaineena 
tutkittiin HEPFAT-dieetti-interventiotutkimuksessa, jossa CK-18:n hyöty intervention 
maksavaikutuksen mittaamissa oli heikko. 
Ydinmagneettiseen resonanssiin perustuvaa spektroskopiaa (NMR) käytettiin 
mittaamaan lipoproteiini-alaluokkien erilaiset lipidit ja pienen molekyylipainon omaavat 
molekyylit 116:lta sairaalloisesti lihavalta henkilöltä. Kokonaiskolesterolimäärä suurissa, 
keskisuurissa ja pienissä VLDL:ssa sekä suurissa ja keskisuurissa LDL:ssa olivat yhteydessä 
maksatulehdukseen maksan rasvoittumisesta riippumatta. Ketoainetasot olivat 
matalammat henkilöillä, joilla oli NASH verrattuna niihin, joilla oli pelkkä rasvamaksa. 
Tämä viittaa alentuneeseen lipidien hapettumiseen ja mitokondrioiden toimintahäiriöön 
niillä, joilla on NASH. 
Tässä väitöskirjatyössä muodostettua ennusteyhtälöä voidaan käyttää NASH:n 
seulontaan yhdessä CK-18:a kanssa. NASH:n yleisyyden takia sen ehkäisemiseen ja 
hoitamiseen tulisi kiinnittää enemmän huomiota. NASH:iin liittyvien kolesteroli-
aineenvaihdunnan muutosten tulisi olla taudin hoitokohteita. Lisäksi tässä työssä todettiin 
vähentynyt lipidien hapetus ja lisääntynyt ketoaineiden hajoaminen niillä, joilla on NASH. 
Tämä väitöskirjatyö osoittaa, että yleiseen NASH-sairauteen liittyy monenlaisia rasva-
aineenvaihdunnan muutoksia. 
 
Luokitus: WI 700, WD 210, WK 810, QU 85.6, QU 95 
Yleinen Suomalainen Asiasanasto: rasvamaksa; maksatulehdus; lihavuus; aineenvaihdunta; diagnostiikka, 
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1 Introduction  
The most common liver disease in the Western world, non-alcoholic fatty liver disease 
(NAFLD), associates strongly with obesity (1,2). NAFLD presents primarily as non-
alcoholic fatty liver (NAFL; fatty liver, simple steatosis), which has been described as a 
phenotype of the metabolic syndrome in the liver (3). Worldwide 20-30% of individuals 
have simple steatosis (4), which can progress to non-alcoholic steatohepatitis (NASH) in 
some subjects (5). Development of scar tissue (fibrosis) may occur in NASH (6), further 
leading to liver cirrhosis and ultimately to end stage liver disease and death (7). NAFLD 
increases the risk of cardiovascular complications and death (8,9). Furthermore, both simple 
steatosis (10) and NASH cirrhosis (11) increases the risk of liver cell carcinoma. 
The major unanswered question is why some individuals with fatty liver will develop 
steatohepatitis. A multiple hits theory has been suggested (12). Cholesterol synthesis is 
proposed to be involved in the pathogenesis of simple steatosis (13) and NASH (14). 
Furthermore, mitochondrial dysfunction (15,16) and endoplasmic reticulum (ER) stress 
(17,18) have been suggested to contribute to the pathogenesis of NASH. Lipid oxidation 
takes mainly place in the mitochondria (19), and impaired lipid oxidation could lead to ER 
stress (20). However, controversial results about lipid oxidation in individuals with NAFLD 
and NASH have been published (16,21-24). 
The diagnosis of NASH requires a liver biopsy (6). Thus, a biomarker or a non-invasive 
score predicting NASH would be very useful. It could be used in clinical practice to find 
those at risk for NASH and would be beneficial in population-based studies, where liver 
biopsy is not possible to obtain. 
In the present study a non-invasive score predicting NASH was developed, and the 
prevalence of NASH in Finnish adults was estimated. In addition, serum CK-18 was tested 
as a marker of NASH in obesity surgery and dietary intervention studies. The metabolic 
changes in individuals with NASH were investigated with focus on the changes in lipid 
metabolism. The following literature review summarizes the scientific literature of NAFLD 
with the main emphasis on the pathogenesis of the disease, the changes in lipid metabolism 
and the diagnostic challenges of the disease. 
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2 Review of literature  
2.1 OBESITY AND METABOLIC SYNDROME 
 
2.1.1 Obesity 
Overweight is defined as body mass index  (BMI defined as weight in kilograms divided by 
the square of the height in meters) equal to or over 25 kg/m2, and obesity as equal to or over 
30 kg/m2 (25). Obesity is defined as abnormal or excess fat accumulation, which may cause 
problems to individual´s health (26). In the last five years, average BMI has increased in the 
vast majority of countries around the World (27) (Figure 1). Worldwide over one billion 
people are overweight (28) and in the USA 70% of adults are overweight and 36% of those 
are obese (29). In Europe over 50% of adults are now either overweight or obese (30). 
Obesity is a serious problem in developed countries (28), but it is also a major health 
challenge in many middle-income countries and its prevalence is increasing also in 
developing countries (31,32). Actually, most of the world population lives in countries 
where obesity causes more deaths than underweight (33). 
 
 
Figure 1. The prevalence of (A) overweighted and (B) obese individuals in different parts of the 
World in the years 2010 and 2014. Adapted from (34). 
 
Obesity causes many problems. It increases the overall mortality at least with BMI ≥ 35 
kg/m2 when comparing to those with BMI < 25 kg/m2 and those with BMI 25-30 kg/m2 (35). 
Furthermore, obesity is risk factor for many diseases such as type 2 diabetes (36), arterial 
hypertension, and cardiovascular diseases (37) (including coronary artery disease (38) and 
stroke (39)), arthrosis (40), gout (41), and cancer (42). In fact, it has been estimated that 
overweight and obesity account for approximately 20% of all cancers (42). 
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2.1.2 Metabolic consequences of obesity 
Obesity is closely linked to metabolic syndrome, which is also known as insulin resistance 
(IR) syndrome (43,44). Metabolic syndrome has been described with at least six different 
criteria (45). The most recent definition of the syndrome requires at least any three of the 
following five components (46): 1) Increased fasting plasma glucose (≥ 5.6 mmol/l) or type 2 
diabetes, 2) hypertriglyceridemia (> 1.7 mmol/L), 3) low HDL cholesterol (< 1.0 mmol/L for 
males and < 1.3 mmol/L for females), 4) increased waist circumference ( ≥ 94 cm for males 
and ≥ 80 cm for females for Caucasians) and 5) hypertension (≥ 130 mmHg for systolic or ≥ 
85 mmHg for diastolic blood pressure), or antihypertensive drug treatment, or history of 
hypertension. 
However, some obese individuals can be metabolically healthy (47,48), and some lean 
individuals can have metabolic syndrome (49,50). It has been estimated that as much as 
30% of obese people are metabolically healthy predominantly because of preserved insulin 
sensitivity (47,50). These individuals are suggested to have more subcutaneous fat but less 
liver fat than unhealthy obese individuals (48). It has been suggested that metabolically 
healthy individuals do not have increased cardiovascular mortality (51), although this has 
been criticized. A meta-analysis evaluated all-cause mortality and cardiovascular events in 
over 61000 individuals finding that also obese subjects with no metabolic abnormalities 
were at increased risk for adverse long-term outcomes. (52) A problem with studies about 
metabolically healthy obesity is that they have had varied criteria for the definition of the 
entity (48,53). 
 
2.1.3 Obesity surgery 
Obesity surgery has rapidly become a more frequent option in the treatment of severe 
obesity. It can induce massive and sustained weight loss of more than 30% two years after 
the operation (54), and sustained weight loss of more than 20% weight loss 20 years after 
the operation (55). European guidelines for the criteria of the surgery are 1) BMI ≥ 40 kg/m2 
or 2) BMI 35-40 kg/m2 and comorbidities like type 2 diabetes, cardiorespiratory disease or 
severe joint disease. BMI for the evaluation may be the current or previous maximum BMI. 
(56) Other guidelines such as those from U.S. National Institutes of Health (NIH) (57) and 
American College of Cardiology (58) have similar criteria. The Food and Drug 
Administration (FDA) has approved gastric banding (GB) as a treatment option in subjects 
with BMI > 30 and at least one obesity associated disease (57). The International Diabetes 
Federation (IDF) suggests that if subject has BMI 30-35 and diabetes cannot be adequately 
controlled by optimal medication, surgery could be considered (59).  
Nowadays, most widely used operation technique is Roux-en-Y gastric bypass (RYGB) 
followed by sleeve gastrectomy and adjustable gastric banding (60). Recently, sleeve 
gastrectomy is becoming the most used procedure in the USA (61). In RYGB, a small 
ventricle pouch is made and part of small bowel is by-passed with alimentary loop. Sleeve 
gastrectomy is based on a technique that shrinks the ventricle loop. (Figure 2) RYGB 
induces more weight loss (approximately 25% more) than less invasive purely restrictive 
GB (7,62). Sleeve gastrectomy brings about successful weight loss, although it is maybe not 
as effective as RYGB (63)  
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Figure 2. Most widely used methods for obesity surgery. 
 
RYGB also causes rapidly efficient improvement in plasma glucose, which is thought to 
result from the stimulation of insulin secretion by increased levels of gut peptides; 
especially postprandial levels of glucagon-like peptide-1 (GLP-1) (64,65). Increased levels of 
GLP-1 together with weight loss are considered as main reasons for the resolution of type 2 
diabetes (65). In fact, RYGB ameliorates type 2 diabetes in approximately 60% of patients 
(64,66). Sleeve gastrectomy has metabolic effects similar to RYGB. However, RYGB might 
provide better glycemic control and more sustained resolution of type 2 diabetes. (63) In 
addition, obesity surgery lowers mortality after the operation (67,68), and has also an effect 
on NASH (69,70-74). 
Common complications after obesity surgery are bleeding, surgical site infection, deep 
venous thrombosis, line leakage and nutritional deficiencies such as B12 vitamin deficiency 
(75). Minor early complications are more frequent in those operated with RYGB compared 
to those having sleeve gastrectomy. No difference in major complications has been noted. 
(76) Up to 50% of patients operated with adjustable GB can have a complication reqiring re-
operation. This is accompanied with a 29% band loss rate. (77) 
2.2 NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) 
2.2.1 Definition and natural course of the disease 
NAFLD is the most common reason for chronic liver disease in the Western world (5). 
NAFLD can present as liver steatosis i.e. NAFL, where triglyceride (TG) content is over 5-
10% in the liver (78). Some individuals will develop inflammatory state described as NASH. 
Importantly, in NAFLD alcohol consumption (defined in European and American 
guidelines) is < 20g of alcohol daily for women and < 30g for men (78). When diagnosing 
NASH, other common causes for liver disease need to be excluded. Usually laboratory tests 
are used to exclude at least viral hepatitis B and C, autoimmune hepatitis and 
hemochromatosis (78,79).  
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Table 1.  Nomenclature associated with non-alcoholic fatty liver disease. Adapted from (78). 
Non-alcoholic fatty liver disease NAFLD - The whole spectrum of the fatty liver disease from 
simple steatosis to steatohepatitis and cirrhosis 
- No significant alcohol consumption                          
(women < 20g/day, men < 30g/day) 
Non-alcoholic fatty liver NAFL - Hepatic steatosis (simple steatosis, fatty liver) without 
hepatocellular injury (ballooning), inflammation and 
fibrosis 
Non-alcoholic steatohepatitis NASH - Hepatic steatosis with hepatocellular injury 
(ballooning) 
- Fibrosis may be present 
NASH cirrhosis  - Liver cirrhosis 
- Previous or current (histological) evidence about 
NAFLD 
Cryptogenic cirrhosis  - Presence of cirrhosis without known etiology, 
metabolic risk factors may be present 
NAFLD activity score  NAS - An unweighted sum of steatosis, inflammation and 
ballooning scores in histological analysis 
- Developed for measuring changes in liver histology in 
clinical trials 
 
Approximately 10-20% of those with simple steatosis have also NASH (4,8). Approximately 
2-3% of patients with steatosis develop NASH during five year follow-up, and up to 8% of 
those with NASH will develop liver cirrhosis in five years. (4,8) Fibrosis has been thought 
to develop in individuals with NASH, but not in those with fatty liver (7,80-82). However, 
lately it has been suggested that liver fibrosis can occur similarly both in simple steatosis 
and in NASH (83). In that study, approximately 40% of individuals had progression in 
fibrosis, but another 40% had not. The presence of type 2 diabetes at baseline was risk factor 
for fibrosis progression. However, the definition of steatosis included also steatosis with 
mild inflammation. (83) This could explain results of fibrosis progression, because mild 
inflammation can be a sign of early NASH. Interestingly, liver fibrosis can also decrease 
during follow-up. Hamaguchi et al. reported that liver fibrosis improved in 31%, 
progressed in 28% and remained unchanged in 41% during a median follow-up of 2.4 years 
(84). Similar results are reported also by Wong et al. (85). 
Both obesity (86) and diabetes (87) are known risk factors for hepatocellular carcinoma 
(HCC). Furthermore, NAFLD also increases the risk of HCC. It is suggested to be 
underlying reason in 35% of HCC cases making it the most common liver disease 
associated with HCC (88). Usually, HCC develops in the cirrhotic liver with the yearly risk 
of 2-3% (11). Alarming finding is that HCC might develop even directly from the fatty liver 
without previous hepatitis or fibrosis (10). 
2.2.2 Prevalence of NAFLD and NASH 
One third of the population in the USA has NAFLD (89). In the many parts of the world, 
the population prevalence is estimated to be at least 20%. In Europe, ultrasound (US) 
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studies have suggested a prevalence of 20-33% (90-95) and 35% of those over 70 years (96). 
In histological post mortem analysis, fatty liver was diagnosed in 31% of individuals 
(n=498, age 3-94 years) in Greece (94). In other parts of the world, the prevalence has been 
estimated to be 19-35% in South America (97,98), 13-17% in China (99,100), 32% in India 
(101,102), 29% in Japan (103,104) and 19-33% in other parts of Asia (105-107). NAFLD is 
much more common in those with type 2 diabetes, with prevalence of 42-94% (108-110). In 
severely obese patients a prevalence of 85-98% has been reported based on the liver biopsy 
(1,111-113).  
The current consensus about the prevalence of NASH is based on the selected groups of 
patients, who have been biopsied for different reasons. The prevalence of NASH has been 
16% in individuals with elevated transaminases with an unknown etiology (114), and 30% 
in those with fatty liver based on US examination (110,115). NASH was found in 40% of 
individuals examined post mortem in Greece (94). This population had mean age of 65 
years, and half of them died of coronary artery disease (94). In addition, in liver donors the 
prevalence of NASH has estimated to be 15% (116). In those evaluated for liver 
transplantation, the prevalence of NASH increased from 1.2% to 9.7% in ten years (117,118). 
Based on these studies, the prevalence of NASH has been suggested to be 1-16%.  
In obese and diabetic subjects the prevalence of NASH is higher. A prevalence of 62-80% 
in type 2 diabetics has been reported (119,120). However, in these studies only those with 
fatty liver in the US examination were biopsied. Thus, the prevalence could be even higher, 
because of limitations of the US (121). In patients undergoing obesity surgery, the 
prevalence estimates have ranged from 23 to 56% (112,113,122-124). 
 
2.2.3 NAFLD and morbidity and mortality 
NAFLD increases both morbidity and mortality. It increases the risk of chronic renal 
disease (125) and cardiovascular diseases such as atherosclerosis (126), stroke (127) and 
atrial fibrillation (128). NASH increases liver-related mortality five to sixfold (129,130) 
when comparing to those without NASH. The most common reasons for death are liver-
related diseases and cardiovascular diseases (9,131). In fact, NAFLD is already the third 
most common cause for liver transplantation in individuals over 65 years old, and is 
suggested to be the most common in the near future (132). Recent publication with 33 year 
follow-up reported that NASH increases risk of death from cardiovascular disease, 
hepatocellular carcinoma, infectious diseases and cirrhosis (9). Previous studies have 
reported that the occurrence of deaths due to cardiovascular disease, liver disease and 
malignity are almost equal (8,131). However, Ekstedt et al. found cardiovascular diseases to 
be a clearly more common cause of death in those with NASH, followed by non-
gastrointestinal malignancies, HCC and infections. Interestingly, those who had mild 
fibrosis (0-2) at baseline were not at an increased risk of death. (9) 
 
2.2.4 Risk factors for NAFLD 
Obesity and physical inactivity. Obesity is the strongest risk factor for NAFLD (1,2), although 
NAFLD can be sometimes present also in lean individuals (133). Physical inactivity is 
suggested to be a risk factor based on the finding that exercise decreases liver fat content 
independently of weight change (134,135).  
Metabolic syndrome and type 2 diabetes. Liver steatosis is closely related to components of 
the metabolic syndrome (1,43,89,136,137). In fact, steatosis can be considered a hepatic 
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manifestation of metabolic syndrome (44). Furthermore, steatosis has been suggested to be 
the most accurate marker of metabolic syndrome, because it is the cause for many 
metabolic components of the metabolic syndrome (79). Type 2 diabetes is a strong predictor 
of NAFLD (108,109). In fact, NAFLD has an association with IR and type 2 diabetes 
independent of obesity (43,138) suggesting that fat accumulation in the liver is essential in 
the development of type 2 diabetes. Finally, lean individuals with NAFLD are also at 
increased risk for diabetes compared to lean controls (133), which highlights the crucial role 
of the liver in glucose metabolism. 
Dietary factors. Excess intake of energy is a risk for NAFLD (139). In addition, the quality 
of diet also affects the risk. A high fat diet increases and low fat diet decreases liver fat 
(140). In addition, excess consumption of carbohydrates is associated with NAFLD (141). 
Higher intake of soft drinks and meat is associated with NAFLD independently of age, 
gender, BMI and total calories. Moreover, a tendency towards lower intake of fish (rich in 
omega-3 fatty acids) has been suggested. (142) Lately, the role of simple sugar intake has 
been discussed actively. High simple sugar intake and especially fructose intake has been 
associated with fatty liver in animal studies (143,144), with type 2 diabetes in humans (145), 
and with liver fibrosis in humans with NASH (146). However, a recent meta-analysis 
suggested that harmfulness of fructose might be simply because of excess energy intake 
(147). Furthermore, a high glucose diet is known to increase cholesterol synthesis more than 
a high fructose diet (148). On the other hand, there are studies reporting that fructose intake 
has an inverse association with the development of fatty liver (146,149). However, in these 
two studies diet was assessed with questionnaires, and intake of fructose was from both 
fruits and sugar-sweetened products (146,149). In the study by Kanerva et al. fruits were a 
major source of fructose for study subjects, which could overcome the possible harmful 
effect of added fructose. 
Age, gender and race. Higher age is associated with the risk of NAFLD (97,105). However, 
older people often have more risk factors for fatty liver (150). Some reports suggest that 
NAFLD is more common in females (122,151,152), but based on newer studies NAFLD is 
more frequent in males (91,105,115,153). However, in lean individuals, NAFLD is more 
common in females (154). 
There is racial difference in the prevalence of NAFLD. The disease is most frequent in 
East Asian Indians (155) and in Hispanics (89). African Americans are reported to less often 
have fatty liver (89). These findings were confirmed in a study with over 9000 individuals 
in the USA (156). Racial differences could be partly explained by differences in genetics 
such as in the frequencies of the known risk genotypes, e.g. Patatin-like phospholipase 
domain-containing protein 3 (PNPLA3) rs738409 genotype (157).  
 
2.2.5 Genetics of NAFLD 
A population based genome-wide association study (GWAS) suggested that 27% of hepatic 
steatosis is explained by genetic factors (158). PNPLA3 (adiponutrin) gene was associated 
with NAFLD in year 2008 (157). Romeo et al. found single nucleotide polymorphism (SNP) 
variant at rs738409 representing a substitution from cytosine to guanine, which results in a 
switch from isoleucine to methionine at residue 148 (I148M). This polymorphism is 
associated with increased liver fat content and aminotransferase levels, but not with BMI 
and type 2 diabetes (157). Interestingly, individuals with NAFLD who have PNPLA3 
rs738409 variant have fewer metabolic abnormalities than those with “common NAFLD” 
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(79,159). PNPLA3 is expressed predominantly in the liver and retina in humans (160), but 
not in adipose tissue as in mice (161). Wild type form of PNPLA3 hydrolyses TGs and the 
I148M substitution abolishes this activity (162,163) explaining the role of PNPLA3 I148M 
variant in increasing liver fat content and the risk of NASH (79).  
Prevalence of PNPLA3 rs738409 heterozygous gene variant is 35-40% and homozygous 
variant approximately 5% in Western populations (164). After finding the association of 
PNPLA3 rs738409 with NAFLD, the genotype has been associated with simple steatosis and 
NASH in many studies. Based on the meta-analysis with 16 studies, homozygous variant 
carriers have 73% higher liver fat content than non-carriers. Those with risk variant have 
also greater risk for liver inflammation and fibrosis. (165) Additionally, PNPLA3 rs738409 
gene variant is associated with increased risk of HCC in those with NAFLD (166), probably 
because it causes more aggressive steatohepatitis and more often fibrosis (167).  
The transmembrane 6 superfamily member 2 (TM6SF2) gene variant at rs58542926 has 
also been associated with NAFLD in a GWAS (168). This variant is an adenine for guanine 
substitution encoding nucleotide 499, which replaces glutamate at residue 167 with lysine 
(E167K) (168). E167K leads to higher hepatic TG content, elevated serum aminotransferases, 
and lower lipid content in serum lipoproteins. (168-170) Prevalence estimate of this variant 
is 7% in Europeans, 3% in Africans, and 5% in Hispanic Americans (168). In a recent study, 
the TM6SF2 rs58542926 genotype was associated with increased risk of NASH. However, 
because this gene variant causes lipid accumulation in the liver, serum lipoprotein lipid 
levels are lower and variant carriers have lower cardiovascular morbidity. (171) 
Other genotypes. Other gene variants have been associated with NAFLD in GWAS and 
confirmed in case-control studies. Neurocan (NCAN) variant at rs2228603 has been 
associated with steatosis, lobular inflammation and fibrosis (158,172). However, TM6SF2 
variant is most likely the causal variant in the same locus with NCAN (168). The 
glucokinase regulatory gene (GCKR) has an essential role in regulating glucose level 
balance (173). Variant rs780094 in GCKR has been associated with NAFLD, NASH and 
fibrosis (158). Variant rs12137855 near the lysophospholipase-like 1 (LYPLAL1) gene has 
been associated with NASH (158), and rs4240624 near protein phosphatase-1 regulatory 
subunit 3b (PPP1R3B) has been associated with steatosis (158). 
Various other genes have also been suggested to associate with NAFLD based on case-
control studies, but their association with the disease needs validation. For example, 
manganese superoxide dismutase is a mitochondrial enzyme taking part in detoxication of 
reactive oxygen species (ROS). This is encoded by superoxide dismutase 2 (SOD2). Lower 
hepatic levels of manganese superoxide dismutase have been associated with NASH (174). 
However, this was a rat study, and the finding could also result from decreased 
mitochondrial function in NASH. Uncoupling protein 2 (UCP2) is a regulator of 
mitochondrial lipid flux and also a regulator of ROS production by the respiratory chain. 
Recently, UCP2 -866 A/A genotype was associated with decreased risk of higher grade 
steatosis and NASH (175). 
 
2.2.6 Pathogenesis of simple steatosis 
In simple steatosis lipids in hepatocytes are mainly TGs that are synthesized from free fatty 
acids (FFA) (176) (Figure 3). Three major sources providing free fatty acids to the liver are: 
1) Most (up to 60%) are from plasma non-esterified fatty acids (NEFAs), deriving mainly 
from lipolysis in adipose tissue. When the storage capacity of adipose tissue is exceeded, 
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serum FFAs will increase (Figure 3). In addition, in IR syndrome insulin does not suppress 
adipose tissue lipolysis enough (13), increasing the influx. Fatty liver also further induces IR 
causing a vicious cycle (177,178). 2) 25% of fatty acids are normally from de novo lipogenesis 
in the liver (13), which is increased threefold in NAFLD (179) (Figure 3). 3) 15% of fatty 
acids derive from dietary fatty acids, which are absorbed from the gut. They are then 
transported in chylomicrons (without esterification) via lymphatic system and vessels, and 
finally chylomicron remnants are taken into the liver. The fatty acid amount deriving from 
the gut increases after a high-fat diet. (13)  
In the liver fatty acids can have three different destinations. First, they can be oxidized 
(i.e. β-oxidation) for energy, which mainly takes part in liver cell mitochondria, but in a 
smaller amount in peroxisomes. Second, fatty acids can be packed as TGs and secreted in 
very low-density lipoproteins (VLDL) from the liver. Third, formed TGs can be stored in 
the liver as lipid droplets. (136) (Figure 3). Because TGs are formed from FFAs, liver 
steatosis can be thought as a protective mechanism from FFA caused lipotoxicity (180).  
 
2.2.7 Pathogenesis of NASH 
Although the pathogenesis of simple steatosis is well known, it is not clear why some 
individuals with simple steatosis will develop NASH. Previously, a two hit hypothesis was 
used to describe the development of NASH (181). Lipid accumulation in the liver has been 
considered as a key element for the pathogenesis of steatosis and being the “first hit” of the 
NAFLD. A “second hit” could be for example lipotoxicity (180,182), mitochondrial 
dysfunction (16), different adipocytokines (183,184), endoplasmic reticulum (ER) stress 
(185), and bacterial endotoxins (186) (Figure 3). 
It is unclear why lipid accumulation is harmful only for some individuals, whereas 
others will never develop NASH. Thus, another yet unclearly understood mechanism is 
needed for development of NASH. Because not just one obvious hit has been found to 
cause NASH, the concept of “first and second hit” has been moved towards “multiple hits” 
theory. It has also been suggested that simple steatosis is a benign process for majority of 
individuals, and NASH could be a separate disease (12). However, this theory is challenged 
by recent findings of fibrosis progression in the liver of those with simple steatosis (83).  
Whatever is the second hit, Kupffer cells and hepatic stellate cells are important 
mediators of the cell injury in NASH. Kupffer cells are resident macrophages that can 
detect damage messages from injured cells and trigger an inflammatory response with 
inflammasome activation. (187,188) Mice studies suggest that Toll-like receptor (TLR) 
activation promotes Kupffer cells to secrete cytokines such as IL-1β (189) and TNF-α (190). 
Furthermore, increased Kuppfer cell content and TNF-α level have been reported also in 
the liver of humans with NASH (191). Stellate cells are activated in the fibrinogenesis in 
NASH (192), in which also Kupffer cells are suggested to participate (193). Stellate cells also 
secrete cytokines and growth factors, which contribute to scar tissue formation in 
fibrinogenesis (187).  
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Figure 3. The multiple hit hypothesis in the pathogenesis of NAFLD. Adapted from (194).  
 
Impaired lipid oxidation. One possible reason for the development of NASH is impaired lipid 
oxidation. Each hepatocyte has about 800 mitochondria, which are mainly responsible for 
lipid oxidation and energy production (19), although a smaller amount of lipid oxidation 
takes place in peroxisomes (195). In mitochondria, fatty acids and glycosylated sugars are 
oxidized (through β-oxidation) to produce acetyl coenzyme A (Acyl-CoA), which enters 
citric acid cycle a.k.a tricarboxylic acid cycle (TCA) (Figure 4). Decreased FFA influx in the 
postprandial state decreases fatty acid oxidation in mitochondria. Insulin and glucose also 
favour de novo lipogenesis regulating the entry of fatty acids inside of the mitochondria. 
(196) When in fasting state or during physical activity blood glucose level decreases, fatty 
acids are oxidized. β-oxidation then produces the ketone bodies acetoacetate (AA) and β-
hydroxybuturate (β-OHB), which thus reflect the rate of lipid oxidation. Ketone bodies 
provide fuel to organs (especially to the brain) (195). 
Impaired lipid oxidation has been reported in those with NAFLD and NASH in some, 
but not in all studies. Low (21), high (16,22,23) and unaltered (24) rate of lipid oxidation has 
been reported based on ketone body levels (Table 2). Impaired lipid oxidation has been 
thought to be caused by abnormal liver cell mitochondrial function (15) or morphology 
(16). Recently, it was found out that obese individuals with or without simple steatosis 
were found to have higher mitochondrial function rates than lean individuals even though 
the liver mitochondrial mass was similar. However, those with NASH had higher 
mitochondrial mass, but 31-40% lower maximal respiratory function than in obese subjects 
without or with simple steatosis. This suggests that mitochondria can adapt their function 
in the early stages of obesity and fatty liver, but this is lost in those with NASH. (20) 
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Table 2. Lipid oxidation in NAFLD based on the β-OHB measurement. 
 
Name Year Patients 
N 
Liver 
biopsies 
Hepatic lipid oxidation Reference 
Sanyal et al. 2001 18 Yes Increased in NASH vs. normal liver (16) 
Chalasani et al. 2003 37 Yes Increased in NASH vs. controls (23) 
Bugianesi et al. 2005 18 Yes Increased in NAFLD vs. controls (22) 
Kotronen et al. 2009 58 No Unaltered in NAFLD vs. controls (24) 
Croci et al. 2012 35 Yes Decreased in NAFLD vs. controls (21) 
Endoplasmic reticulum stress. Lipid accumulation and altered lipid oxidation can disturb ER 
function. ER is a membranous organelle that has important functions such as folding and 
modification of proteins, synthesis of phospholipids and a function as an enzyme such as 
cytochrome P450 (197,198). Both obesity (199) and hepatic steatosis (17) are known to 
induce ER stress in the liver. Interestingly, ER stress can induce hepatic steatosis (200) and 
inhibit VLDL secretion in experimental models (201), leading to lipid accumulation and 
more ER stress. Thus, ER stress is both a cause and consequence for lipid accumulation in 
the liver.  
When ER stress is present, the unfolded protein response (UPR) pathway is activated, 
aiming to restore homeostasis and reduce the transfer of proteins into ER lumen (202). The 
UPR pathway also has an important role in hepatic lipid homeostasis (203). The UPR 
pathway is activated both in steatosis and NASH (204). When the pathway cannot restore 
normal ER balance, it induces apoptosis. (182) Inositol requiring enzyme 1 alpha (IRE1α) is 
one of the three ER transmembrane receptors (182). The IRE1α pathway takes part in ER 
stress-induced apoptosis. It can also activate c-Jun N-terminal kinase (JNK) (205,206), which 
promotes inflammation and apoptosis in the liver (182). IRE1α also links to lipid 
metabolism via activating X-box binding protein 1 (XBP1), which can directly activate key 
lipogenic genes (203). When XBP1 is suppressed, de novo lipogenesis is decreased (207). 
Active spliced XBP1 protein is decreased in individuals with NASH (204), suggesting a link 
between lipid metabolism and ER stress. 
 
2.2.8 Lipid metabolism in NAFLD 
Lipid metabolism has a key role in the pathogenesis of NASH. As described above (2.2.6), 
increased FFA influx and lipogenesis in the liver may contribute to NAFLD (13). Increased 
FFA influx and lipogenesis have also been associated with NASH (14,208,209). 
Additionally, cholesterol synthesis is increased in those with NAFLD (210,211) and NASH 
(212). Furthermore, secretion of VLDL has been reported to be increased in those with 
NAFLD (137,213). Interestingly, decreased secretion of VLDL was reported in NASH (213). 
These mechanisms contribute to TG and cholesterol accumulation and lipotoxicity in the 
liver. Genetic studies of PNPLA3 and TM6SF2 also support the idea that the balance 
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between lipid accumulation and secretion in VLDL is crucial in the development of NASH 
(157,171,214). Importantly, Fujita et al. reported similar liver TG content in those with 
steatosis and in NASH (213) suggesting that factors beyond TG accumulation are needed to 
cause inflammation and cellular damage. In the following, normal fatty acid and cholesterol 
synthesis pathways in the liver, mostly in the hepatocytes, are described with references to 
disturbances in these pathways in NASH. 
Fatty acid metabolism. Fatty acids and cholesterol have separate metabolic pathways in the 
liver hepatocytes (Figure 4). Fatty acid translocase (CD36) is responsible for FFA uptake 
into liver (together with fatty acid transport proteins). Fatty acid synthesis is regulated by 
carbohydrate-responsive element-binding protein (ChREBP) activated by glucose 
independently of insulin (215), whereas sterol regulatory binding protein-1c (SREBP-1c) is 
activated by insulin (216). SREBP-1c is a master regulator of fatty acid metabolism with 
important target genes, such as fatty acid synthase (FASN), acetyl CoA carboxylase (ACC) 
and stearoyl-CoA desaturase (SCD1) (215,216), regulating fatty acid synthesis. Increased 
SREBP-1c expression in the liver has been associated with NAFLD in mice (217) and in 
humans (218), potentially because of hyperinsulinemia (13). However, SREBP-1c is not 
upregulated in those with NASH (219). In fact, Nagaya et al. found decreased SREBP-1c 
expression in those with advanced fibrosis (219). SCD1 activity is negatively associated 
with liver fat content after high sugar diet in healthy subjects, suggesting increased fatty 
acid desaturation. (220)  
Fatty acids are converted to TGs by diacylglycerol O-acyltransferase 2 (DGAT2), which 
has been suggested to be have an important role linking simple steatosis and IR possibly 
because of altered amounts of fatty acid metabolites regulating insulin sensitivity (221). If 
TGs are not formed normally, it decreases hepatic steatosis, but causes FFA accumulation, 
which can cause inflammation and liver injury. (180) After TG formation, microsomal 
triglyceride transfer protein (MTTP) packs TGs into VLDL (222). The function of MTTP 
may be decreased in those with NASH compared to those with simple steatosis. (213) 
Cholesterol metabolism. LDL cholesterol from the circulation is taken into the liver via 
LDL-receptor (LDLR) -mediated endocytosis regulated by Proprotein convertase 
subtilisin/kexin type 9 (PCSK9) (222). Cholesterol synthesis takes place in the ER, where the 
rate-limiting enzyme is HMG-CoA reductase (HMGCR) (223). Both messenger RNA 
(mRNA) expression and protein levels of HMGCR are increased in those with NASH (224). 
Sterol regulatory binding protein-2 (SREBP-2) and liver X receptor (LXR) are major 
regulators in cholesterol metabolism (218,222,225). SREBP-2 is a transcriptional regulator of 
HMGCR, and it also activates LDLR (225).  
LXR is an important sterol sensor regulating cholesterol homeostasis (226), but it also has 
a role in fatty acids metabolism. LXR regulates cholesterol catabolism and secretion into 
bile (Figure 4 and 5) (227). Increased LXR expression has been associated with NASH and 
fibrosis in human liver (218). Normally, excess intracellular cholesterol inhibits SREBP-2 
and activates LXR, leading to cholesterol export and elimination. Moreover, a decrease in 
intracellular cholesterol content causes SREBP-2 induced cholesterol synthesis and uptake. 
(222) However, increased mRNA expression (228) and SREBP2 protein content (224) in the 
liver have been reported in those with NASH, suggesting increased cholesterol synthesis, 
even though liver cholesterol content is increased (210,211) Interestingly, dietary cholesterol 
and synthetic LXR agonists have been reported to increase SREBP-1c expression by LXR, 
suggesting a link between hepatic cholesterol and TG metabolism (226). 
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Mice with null LXR have shown activation of stellate cells, which could participate in the 
development of liver cell fibrosis. In LXR null mice retinoid (storage form of vitamin A) 
levels are increased in the stellate cells suggesting possible role of retinoid metabolism in 
the progression of NASH. (229). Recently, PNPLA3 was found to function as a lipase 
responsible for retinyl-palmitate hydrolysis in human stellate cells (160). Interestingly, the 
expression of PNPLA3 is regulated by ChREBP and by SREBP-1c (215), supporting the 
major importance of PNPLA3 in liver lipid metabolism.  
 
 
Figure 4. Lipid and lipoprotein pathways in the liver, modified from (222). Glucose and insulin 
activate transcription factors SREBPs and ChREBP, which are needed for synthesis of fatty acids 
and cholesterol. Increased lipogenesis leads to an increase in VLDL production. Liver uptake of 
LDL is via LDLR. Metabolic genes are in italics and black lines demonstrate metabolic pathways. 
Red lines demonstrate transcriptional regulation. Green ovals symbolize mitochondria. 
 
Liver free cholesterol accumulation in NASH. Together with increased cholesterol synthesis 
(14,210,211), liver free cholesterol accumulation has a major role in NASH (210,228,230). 
Reduced cholesterol intake has been reported to decrease hepatic free cholesterol levels and 
NASH in mice (230), supporting the importance of cholesterol metabolism in the 
development of NASH. Intracellular cholesterol content is normally tightly regulated by 
mechanisms affecting cholesterol uptake, synthesis, catabolism and export (222). If these are 
disturbed, free cholesterol can accumulate in the cells and cause injury (231). In the 
following, several possible reasons for free cholesterol accumulation are covered: 
1)  Disturbed intracellular cholesterol trafficking. Inside the liver cell LDL cholesterol is 
hydrolyzed by Niemann-Pick disease, type C1 (NPC1) and free cholesterol is released (232) 
Next, cholesterol is carried to Acyl CoA-cholesterol acyltransferase (ACAT) in the 
endoplasmic reticulum, where cholesterol is esterified to the storage form (cholesterol 
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esters, CEs) (Figure 5). However, increased cholesterol de-esterification in NASH is 
suggested by increased expression of hepatic neutral cholesterol ester hydrolase (NCEH) 
(224,231). This can increase the free cholesterol content. Additionally, ATP-binding cassette 
transporter A1 (ABCA1) controls the cholesterol absorption and secretion (233) and its 
expression is reduced in those with NASH (224). 
2) Altered cholesterol excretion into bile. Bile acids are important in cholesterol 
metabolism. Even under unlimited availability cholesterol is excreted into bile (234). Tumor 
necrosis factor alpha (TNF-α) can activate cholesterol synthesis, but also inhibit cholesterol 
elimination through bile acids in mice (235), suggesting a possible role also in NASH. 
Niemann-Pick C1-like 1 (NPC1L1) receptor regulates the amount of cholesterol excreted 
into bile together with ATP-binding cassette transporters G5 and G8 (ABCG5/8) (234,236). 
NPC1L1 is also important in cholesterol uptake from the gut (234). Liver NPC1L1 gene 
expression correlates negatively with liver cell inflammation (and with LXR expression) in 
humans (218). In mice with IR, ABCG5/8 expression is increased, leading to increased 
biliary cholesterol excretion (237), but this has not been confirmed in humans (224). The 
farnesoid X receptor (FXR) is a nuclear receptor that is activated by elevated levels of bile 
acids. FXR attempts to limit accumulation of toxic metabolites (Figure 5). It has an 
important function regulating hepatic de novo lipogenesis, VLDL-TG export and plasma 
TG turnover. (238) Liver FXR function is defective in those with NASH, leading to 
increased bile acid levels (209), which could cause liver injury. However, also decreased 
bile acid synthesis in those with NASH has been suggested. CYP7A1 and CYP27A are 
needed for the catabolism of cholesterol to bile acids and these are down-regulated in those 
with NASH (224), which could increase cholesterol content in the liver. 
3) Increased cholesterol excretion (14,210,211) together with decreased cholesterol intake 
via LDLR has been reported in those with NASH (224). However, defective VLDL secretion 
has also been found in those with NASH (213), suggesting that increased cholesterol 
synthesis (212) together with decreased lipid outflow from the liver could lead to 
cholesterol accumulation (Figure 4).  
 
 
Figure 5. Cholesterol trafficking in the liver cell and excretion into the bile. Modified from (239). 
Red arrow demonstrates transcriptional activity of genes regulating cholesterol metabolism. 
Black dotted line demonstrates activation of FXR and LXR. 
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 Free cholesterol toxicity in NASH. It is unclear why free cholesterol is toxic for the liver. It has 
been suggested that it can directly cause apoptosis and liver cell necrosis (240). Free 
cholesterol accumulation in stellate cells can possibly activate inflammatory pathway and 
lead to NASH. (241) Additionally, free cholesterol can activate TNF-α and Fas ligand (242), 
which promote hepatic inflammation (243,244). Free cholesterol accumulation links also 
with JNK activation, oxidative stress and mitochondrial membrane alterations in mice with 
NASH (240). 
Free cholesterol toxicity could also be explained by its effect on mitochondria. 
Cholesterol concentration in the mitochondria is normally much lower (3-5% of the total 
cellular cholesterol) than in the plasma membrane. Mitochondria are very sensitive for the 
increase in the cholesterol content, which can disrupt the membrane function (245). Free 
cholesterol accumulation (but not TG or FFA accumulation) can cause mitochondrial stress 
and ROS (243,244). This is accompanied by defective mitochondrial function (15,20,21). 
Steroidogenic acute regulatory protein (StAR) takes part in cholesterol transport to 
mitochondria. Interestingly, liver StAR expression has been reported to be higher in those 
with NASH than in those with steatosis. (228)  
Importantly, mitochondria are responsible for producing the major part of ROS (246). 
When mitochondrial ROS production exceeds cell´s antioxidative capacity, it can damage 
cell lipids, proteins and nucleic acids. This leads to oxidative stress and liver cell apoptosis 
(197). The intact mitochondrial glutathione pool is essential for controlling the formation of 
ROS (245,247). However, increased mitochondrial free cholesterol content impairs 
glutathione transport (242), which could further lead to increased mitochondrial ROS 
generation and cell injury. Furthermore, free cholesterol accumulation modifies the free 
cholesterol to phospholipid ratio in ER membrane and makes the membrane too stiff. This 
leads to ER stress and impaired ER function. (197) Thus, free cholesterol can also directly 
disturb ER function in addition to disrupting mitochondrial function and causing ER stress 
(18). 
 
2.2.9 Diagnosis of NAFLD  
NAFLD is the most common cause for elevated liver enzymes such as alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) (4). However, if NAFLD 
diagnosis is based on elevated transaminase levels, up to 80% of patients with NAFLD can 
remain undiscovered (89).  
Liver steatosis can be diagnosed with easily accessible abdominal US, with sensitivity of 
60-94% and specificity of 66-97% (248-250). Nonetheless, conventional US examination does 
not reveal mild steatosis (steatosis under 30%) (121), although newer US devices have better 
accuracy. Quantitative US models have been developed, and they detect mild stetosis better 
than conventional US (251). Computed tomography (CT) detects steatosis well, and in fact 
detects local steatosis better than US. However, CT cannot be used as a screening method, 
because of radiation exposure. (252) Of the standard methods, magnetic resonance imaging 
(MRI) is the best and can reliably detect steatosis of 3% (253). 
Magnetic resonance spectroscopy (MRS) has become a non-invasive gold standard for 
finding liver steatosis. MRS may even be more reliable than liver biopsy for this purpose, 
because it assesses the whole liver volume (254). MRS diagnosed steatosis correlates well, 
but not perfectly with liver biopsy-assessed steatosis grading (255). However, it should be 
remembered that MRS measures the amount of TGs in the parenchyma and histological 
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evaluation is based on the number of hepatocytes affected by steatosis (254). Sensitivity of 
MRS is so high that it can detect even very small amounts of TGs, which are perhaps not 
seen on histological analysis (252). The use of MRS is limited because of the expensive and 
not widely available methodology. Additionally, liver cell inflammation and fibrosis (254) 
cannot be currently detected by MRS. Therefore, MRS cannot replace liver biopsy when 
evaluating NASH.  
 
2.2.10 Non-invasive diagnosis of NASH 
Diagnosis of NASH is challenging without histological analysis Elevated ALT and AST 
levels may raise the suspicion of NASH (4), although transaminases can be normal in those 
with NASH (89). When a cut-off value < 35 IU/L for ALT is selected, a sensitivity of 89% 
and specificity of 29% for finding NASH have been achieved. When selecting cut-off values 
of 53-70 IU/L, sensitivity is 50-72% and specificity is 51-61%. (256) AST to ALT ratio has 
been used to differentiate alcoholic and non-alcoholic steatohepatitis. A ratio < 1 suggests 
non-alcoholic disease, and a ratio > 2 is strongly suggestive for alcoholic disease (257), 
although ratio > 1 predicts advanced fibrosis in those with NASH (258).  
Serum cytokeratin-18 (CK-18) for finding NASH. Since liver transaminases are far from 
optimal to find subjects with NASH (89,256) other non-invasive markers have been studied. 
Liver cell apoptosis activates intracellular proteases such as caspase-3 and caspase-7 (259). 
These proteases can cleave intracellular substrates, such as CK-18, which is the major 
filament protein in the liver (259). Thus, it has been suggested that serum CK-18 could be 
used as a marker of liver cell injury. Both serum total CK-18 (uncleaved, M65 antigen) and 
its fragments (cleaved, M30 antigen) have been tested in finding those with NASH (260). 
Increased concentrations of serum CK-18 M30 have been associated with liver cell injury 
in those with NASH (261,262). Diab et al. reported sensitivity of 82% and specificity of 77% 
with a CK-18 cut-off value of 252 U/L. When the cut-off was elevated to 275 U/L, sensitivity 
of 77% and specificity of 100% were achieved. (261) Feldstein et al. published similar results 
(262) and CK-18 M30 was suggested to be the best biomarker for finding those with NASH, 
although in another study the accuracy was not very good (sensitivity and specificity of 
66%) (263). The Guidelines of American Gastroenterological Association (AGA) and 
American Association for the Study of Liver (AASLD) state that CK-18 is a promising 
biomarker for finding those with NASH, but it is too early to recommend CK-18 in clinical 
practice (78). Since these guidelines, its sensitivity to separate NASH from simple steatosis 
has been questioned (264,265). Cusi et al. reported that CK-18 is a good predictor for 
steatosis and fibrosis, but not for NASH (sensitivity of 58% and specificity of 68%) (264). 
However, a meta-analysis with total of 838 individuals reported a sensitivity of 83% and 
specificity of 71% for CK-18 M30 for diagnosing NASH. Total CK-18 concentration had a 
sensitivity of 77% and specificity of 71% for finding those with NASH. This suggests that 
CK-18 measurement is useful, but it works better in screening than in diagnosing NASH. 
(260) 
Non-invasive scores. At least 15 non-invasive scores have been developed to detect NASH 
(112,124,266-278). These scores have tested how the combination of NASH-related 
biomarkers associates with histological diagnosis of NASH. Scores are composed of routine 
measures such as age, components of the IR/metabolic syndrome (BMI, TGs, glucose, 
insulin, hypertension), liver enzymes, platelets, albumin, CK-18, circulating collagen 
peptides and various inflammatory markers (254).  
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A NASH score consisting alpha-2-macroglobulin, haptoglobin, apolipoprotein A1, total 
bilirubin, gamma-glutamyl transferase (GGT), ALT, AST, TGs, cholesterol, age, gender, 
height and weight (267) is one of those few that have been externally validated, but it does 
not find NASH accurately enough (279). In addition, many scores for finding fibrosis have 
been developed, of which the NAFLD Fibrosis Score (258) is the most studied. The score is 
formed using age, BMI, hyperglycemia, platelet count, albumin, and AST/ALT ratio (258). 
The guidelines of the AASLD/AGA consider it as a clinically useful tool for identifying 
those with a higher likelihood of having bridging fibrosis and cirrhosis among those with 
NAFLD (78). However, critical comments have been made considering its accuracy for 
predicting NASH (280).  
A problem with many of these scores is that they can perform well in the discovery 
cohort, but cannot find NASH equally well in validation cohorts. In addition, many of those 
that have worked well in discovery cohorts are complicated and not easy to implement in 
daily practice. Glolam´s model is composed of easily available variables (AST and presence 
of diabetes), but the accuracy of this score is not excellent (124). (Table 3)  
Imaging methods. In recent years, elastography methods have been developed as non-
invasive procedures to find liver fibrosis based on changes in liver elasticity. Transient 
elastography (like Fibroscan, Echosens, Paris, France) can be performed rapidly at the 
bedside. It is based on an US method measuring liver stiffness, and has primarily been used 
in hepatitis B and C patients to evaluate the grade of liver fibrosis. (281) However, there are 
promising results also in NAFLD patients for detecting higher grade fibrosis (grade 3 and 
4) (281,282). US examination with bubble contrast media has shown excellent accuracy for 
finding all grades of fibrosis, and may potentially be used for detecting fibrosis in the future 
(283). Finally, MR elastography has better accuracy for finding liver fibrosis than US 
elastography suggesting that it could be used more widely in the future (284). However, it 
should be highlighted that these methods are for finding scarring fibrosis, and none of the 
imaging procedures can detect liver cell inflammation. 
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Table 3. Non-invasive scores for NASH. 
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2.2.11 Histological diagnosis of NASH 
Although imaging procedures can detect steatosis and possibly also fibrosis in the future, 
liver inflammation can currently be diagnosed only with liver biopsy (6,285). In liver 
biopsy, the main measures are steatosis, liver cell ballooning as a marker of hepatocellular 
injury, and lobular inflammation. In more detail, steatosis is evaluated primarily from 
perivenular area (Figure 6). Steatosis is graded as mild (<33%), moderate (33-66%) and 
severe (>66%) based on percentage of liver cells with fat accumulation. Severe steatosis can 
be present in the whole acinus (Figure 6). (6) Lobular inflammation is usually mild, and the 
inflammatory cells that are present are lymphocytes, eosinophils and possibly neutrophils. 
Inflammatory cells in lobular area (no foci = 0, <2 inflammatory foci per 200 x field = 1, 2-4 
foci per 200 x field = 2 and >4 foci per 200 x field = 3) are evaluated. In addition, portal 
mononuclear inflammation can be present as a feature of more advanced disease (286). 
Kupffer cells can aggregate and form microgranulomas, which can be present in addition to 
lipogranulomas (6). Liver cell ballooning is an important feature in NASH, and it is 
associated with more aggressive disease (287). Ballooning is graded as minimal (0), present 
(1) or marked (2).  
Although fibrosis is considered the unwanted outcome of NASH, its presence is not 
required for the diagnosis at the earlier stages of the disease. It usually starts from acinar 
zone 3 (Figure 6) and has a “chicken wire” pattern. In addition, portal fibrosis can be 
present. In more severe disease bridging fibrosis and liver cirrhosis can occur. (6) Cirrhosis 
in NASH is normally macronodular or mixed, but not micronodular (288). In addition, 
other NASH-associated features might be found in histological evaluation. These include 
Mallory-Denk bodies (289), which associate with the severity of NASH (6) and strengthen 
the NASH diagnosis, but they can be seen also in other forms of steatohepatitis (such as 
alcoholic steatohepatitis) (288). Mallory bodies contain misfolded keratins like CK-18 (290). 
There can be megamitochondria and glycogenated nuclei, which are only rarely seen in 
alcoholic steatohepatitis (288). 
 
 
 
Figure 6. Liver acinus, the functional unit of the liver. 
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The NAFLD activity score has been developed to detect NASH (NAS; Table 4) combining 
evaluation of steatosis, hepatocellular ballooning and lobular inflammation. It should be 
noted that NAS was primarily formed as a tool for finding NASH in intervention studies 
(285). NAS over 5 suggests NASH, and score under 3 suggests the absence of NASH. Later, 
the prognostic value and the benefit of the score have been questioned (291-293). 
Additionally, a NASH activity grade combining the evaluation of steatosis, ballooning and 
lobular and portal inflammation has been used (6). 
The liver biopsy is a relatively safe procedure, but can have even fatal complications, 
with a death rate of 0.01% (294). It also has some other limitations. First, adequate sized 
liver biopsy for histological analysis with approximately 10 portal tracts (295), is still only 
1:50 000-1:65 000 of the whole liver size and thus only local analysis of lipid accumulation 
in the liver is performed (6). Accordingly, inflammatory lesions may be scattered in the 
liver, which could wrongly exclude NASH in as many as one third of cases (296,297). 
Second, interpretation of liver biopsy depends on the pathologist, leading to potential bias 
(6). Therefore, analysis should be made by an experienced pathologist. 
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Table 4. Histological variables analyzed in diagnosing NASH, also showing coding for the NAFLD 
activity score. 
 Definition 
 
Score/code 
 
Steatosis    
      Grade  
      <5 % 0 
      5-33 % 1 
      33-66 % 2 
      >66 % 3 
      Location  
      Zone 3 0 
      Zone 1 1 
      Azonal 2 
      Panacinar 3 
 Microvesicular Steatosis  
      Not present 0 
      Present 1 
Fibrosis   
 Stage  
      None 0 
      Perisinusoidal or periportal 1 
      Mild, zone 3, perisinusoidal 1A 
      Moderate, zone 3, perisinusoidal 1B 
      Portal/periportal 1C 
      Perisinusoidal and portal/periportal 2 
      Bridging fibrosis 3 
      Cirrhosis 4 
Inflammation   
 Lobular inflammation  
    None 0 
      <2 foci per 200x field 1 
      2-4 foci per 200x field 2 
      >4 foci per 200x field 3 
 Microgranulomas  
      Absent 0 
      Present 1 
 Large Lipogranulomas  
      Absent 0 
      Present 1 
 Portal inflammation  
      None to minimal 0 
      Greater than minimal 1 
Liver cell 
 
  
 Ballooning  
      None 0 
      Few balloon cells 1 
      Many cells/prominent ballooning 2 
 Acidophil bodies  
      None to rare 0 
      Many 1 
 Pigmented macrophages  
      None to rare 0 
      Many 1 
 Megamitochondria  
      None to rare 0 
      Many 1 
Other 
 
  
 Mallory’s hyaline  
      None to rare 0 
      Many 1 
 Glycogenated nuclei  
      None to rare 0 
      Many 1 
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2.2.12 Management of NAFLD  
The most important treatment for NAFLD is lifestyle modification, because it is easily 
available and most effective. Lifestyle changes aim for weight reduction. Weight loss of 5% 
has resolved NAFLD in as many as 75% of subjects. (298) Similar weight loss has improved 
IR and liver steatosis in NASH, but weight loss of 7-9% is needed for improvement in 
inflammation and ballooning (299,300). Thus, a weight loss of 3-5% in those with simple 
steatosis, and 7-10% in those with NASH is recommended (78). It seems that weight loss of 
at least 10% is needed for fibrosis improvement (301). 
Calorie restriction is essential for weight loss. A diet should contain 600 Kcal less than is 
needed for remaining weight stable with a target of 0.5-1.0 kg weight reduction per week.  
(302) The amount of dietary fat should be reduced, because high fat diet increases and low 
fat diet decreases liver fat (140). In addition, the quality of fatty acids may be important, 
because high amount of monounsaturated fatty acids in a diet reduces hepatic steatosis 
(303). Both omega-3 (304) and omega-6 fatty acids (305) have also shown potential in 
reducing liver fat. 
Higher level of physical inactivity is associated with lower levels of steatosis (306,307). 
Interestingly, physical activity improves liver enzymes and decreases liver fat 
independently of weight loss (308,309). Physical activity also improves NASH (299,310).  
Massive weight loss induced by obesity surgery has been shown to lead to resolution of 
NASH. Steatosis (311,312), inflammation (71) and fibrosis (70,71,311-313) have been 
reported to decrease after surgery. In a Cochrane analysis, authors could not find any 
randomised clinical trials fulfilling the inclusion criteria. However, 21 prospective or 
retrospective cohort studies reported improvement on steatosis or inflammation (74). 
Randomized studies are still needed. However, the challenge in these studies is to justify 
taking follow-up liver biopsies in a setting where clinical improvement is very likely and 
thus biopsies do not provide additional information. 
The quality of the diet is also important. The role of fructose in the development of 
NAFLD is unclear (143,144,146,147,149). However, excess amounts of simple sugars should 
be avoided, because they cause weight gain (314) and increase liver fat content (315). Small 
amounts of alcohol might reduce the risk of NASH (112), but the safe limit is not known. 
Surely, heavy drinking is not recommended (78), and it might be wise to advise these 
individuals to avoid alcohol. Coffee drinking might protect from disease progression, at 
least for severe fibrosis (316), so it should not be forbidden. 
Drug treatment has only a small role in treatment of NASH. In special occasions, like in 
young people with NASH or advanced fibrosis, vitamin E and pioglitazone could be 
considered as a treatment option (78,317). However, it should be noted that there are no 
Food and Drug Administration (FDA) approved drugs for the treatment of NASH (318). 
Table 5 summarizes the current knowledge about the drug treatment of NAFLD. 
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Table 5. Drug therapy for NAFLD. Modified from (317)  
 
Benefit Agent Results 
Potential benefit – could be 
considered for the treatment 
Pioglitazone Improved liver histology both in non-diabetic (319) 
and diabetic individuals  
Caused weight gain (320) 
Risk of congestive heart failure (321), osteoporosis 
(322) and possible increase in the risk for bladder 
cancer (323) 
 Vitamin E Improved liver histology (dose 800 IU/d) (320) 
Increased risk for stroke (324), prostate cancer (325) 
and overall mortality (326) 
No clear benefit –should be 
studied further 
Metformin Effect in steatosis (327) and inflammation (328) in 
mice studies  
Unclear effect based on human studies (329-331) 
 Statins Improvement in transaminases and decrease in liver 
fat content (332) 
Those with statin have less steatosis, inflammation 
and fibrosis (333)  
 Ezetimibe Decreased fibrosis and ballooning. Worsened insulin 
sensitivity (334) 
 Pentoxifylline In small studies improved histology (335,336) and ALT 
(335,336) 
 UDCA No improvement in liver histology (dose 23-28 
mg/kg/d). However, lobular inflammation seemed to 
improve (337) 
New treatment ideas – should 
be studied further 
GLP-1 analogues  Decreased intrahepatic lipid content in humans (338) 
 Anti-TNF-α-
agents  
Improved NASH in mice (339) 
 Probiotics  Improved NASH in mice (340) and decreased AST in 
humans (339)  
 Resveratrol SIRT1-activator has showed potential of decreasing 
NASH in mice (341) 
 LXR-inverse 
agonist 
Reversion of NASH in mice (342) 
 Obeticholic acid Farnesoid X nuclear receptor agonist reduced 
steatosis, inflammation and fibrosis in humans, 
associated with the development of dyslipidemia (343) 
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3 Aims of the Study 
 
The aim of this thesis was to investigate metabolic disturbances in individuals with NASH 
and compare them to those with normal liver and those with simple steatosis for the 
purpose of finding biomarkers for NASH. The more specific aims were to: 
 
1. Form a non-invasive score for predicting NASH and estimate the 
population prevalence of NASH in Finnish adult individuals (I) 
 
2. Investigate serum CK-18 as a biomarker of NASH in dietary and surgical 
intervention studies (I and II) 
  
3. Analyze lipoprotein subclass metabolism in NASH (III) 
 
4. Evaluate lipid oxidation and ketone body metabolism in NASH (IV)  
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4 Methods 
4.1 STUDY SUBJECTS 
 
4.1.1 Kuopio Obesity Surgery Study (KOBS) 
The primary study population of this thesis was 116 subjects from Kuopio Obesity Surgery 
Study (KOBS) (studies III and IV). In study II, 124 individuals from the KOBS were 
included. Patients were recruited amongst Kuopio University Hospital patients eligible for 
laparoscopic gastric bypass operation. Criteria for the surgery were (1) BMI > 40 kg/m2 or 
(2) BMI 35-40 kg/m2 and a comorbidity or its risk factor, such as type 2 diabetes, 
hypertension, sleep apnea, osteoarthritis of weight bearing joints or polycystic ovarian 
syndrome; and (3) previous conservative treatment for obesity was proven to be ineffective. 
These criteria are in line with European guidelines (56). Written informed consent was 
obtained. Chronic hepatitis B and C were excluded using serologic tests if ALT values were 
elevated prior to surgery. Alcohol consumption < 20 g per day was required as an inclusion 
criterion. Every subject participated in one-day visit including an interview on the history 
of previous diseases and current drug treatment. During the week preceding the elective 
obesity surgery operation, blood samples were taken after an overnight fast. Control 
samples were obtained 12 months after the surgery 
 
4.1.2 Helsinki-Kuopio cohort  
In studies I and IV an extended cohort with 296 obesity surgery patients from Kuopio and 
Helsinki was also included (n=129 in Kuopio and n=167 in Helsinki). Of these, 89 were 
same individuals as in the KOBS described above. Criteria for surgery were similar to 
KOBS cohort. Inclusion criteria were (1) age 18–60 years; (2) no known acute or chronic 
disease except for obesity or type 2 diabetes, hypertension, sleep apnea, osteoarthritis of 
weight bearing joints or polycystic ovarian syndrome based on history, physical 
examination, standard laboratory tests (blood counts, serum creatinine, thyrotropin, and 
electrolyte concentrations) and electrocardiogram; (3) alcohol consumption < 20 g per day. 
 
4.1.3 Validation cohort from Italy 
In study I an Italian cohort with 380 patients from the Metabolic Liver Diseases Outpatient 
Service (Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico) was also used. 
These patients were diagnosed of having NAFLD between January 2008 and January 2010. 
A liver biopsy was performed in 309 (81%) of patients because of persistently abnormal 
liver enzymes or serum ferritin, or a long lasting history of steatosis associated with severe 
metabolic abnormalities. Seventy-one (19%) of patients were obesity surgery patients. Other 
causes of liver disease were excluded, including excess alcohol intake (>30 g/day for men 
and 20 g/day for women), viral and autoimmune hepatitis, hereditary hemochromatosis, 
and alpha1-antitrypsin deficiency.  
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4.1.4 D2D population study 
In study I a cohort from national type 2 diabetes prevention programme (FIN-D2D) was 
used to assess the prevalence of NAFLD based the non-invasive score developed. D2D 
study was carried out in three hospital districts in Finland in year 2007 (344). 4500 subjects 
were stratified according to gender, 10-year age groups (45-54, 55-64 and 65-74 years) and 
three geographical areas. Total number of participating individuals was 2849 (63% of the 
original sample). Men consuming ≥ 40 g and women ≥ 20 g of ethanol per day based on the 
past week data were excluded from the study I. The health examination was carried out 
according to the WHO MONICA project protocol (345). This cohort had detailed routine 
measurements and PNPLA3 rs738409 genotyping available.  
 
4.1.5 METSIM population study 
A total of 8749 non-diabetic men from the population-based cross-sectional METSIM 
(Metabolic Syndrome in Men) study (346) were included in study IV. The METSIM study 
was performed in 2005-2010. Subjects aged from 45 to 70 years were randomly selected 
from the population register of the town of Kuopio, Eastern Finland (population of 95 000). 
Their age was 57.2 ± 7.1 years and BMI 26.8 ± 3.8 kg/m2. Every participant had a 1-day 
outpatient visit to the Clinical Research Unit at the University of Kuopio, including an 
interview on the history of previous diseases and current drug treatment and an evaluation 
of glucose tolerance and cardiovascular risk factors. Fasting blood samples were drawn 
after 12 h of fasting followed by an oral glucose tolerance test. Serum ALT was used as the 
marker of liver disease in this study. Ketone body levels were determined with serum NMR 
analysis (347). Consumption of alcohol in this population was 14 ± 19 g per day. 
 
4.1.6 HEPFAT dietary intervention 
In study II, diet intervention study population was included. The Role of Dietary Fatty 
Acids in Fatty Liver and Insulin Resistance (HEPFAT) Trial was a randomized, 10-week, 
parallel-group study conducted in Uppsala, Sweden, between February 2009 and April 
2010 (305). The study group consisted of 67 individuals. Participants were randomly 
assigned to either a polyunsaturated fatty acid (PUFA) or saturated fatty acid (SFA) diet. 
The primary outcome was change in liver fat content measured by MRI and by MRS. Those 
56 participants who had CK-18 measured and liver fat assessed by MRS before and after the 
intervention were included in the study II. Of these, 27 had been randomized to the n-6 
PUFA diet and 29 to the SFA diet. When study subjects were divided to those with low 
liver fat (<5%) and those with high liver fat (>5%) content, 35 individuals were in low liver 
fat (mean 1.9 ± 1.3%) group and 21 individuals in high liver fat group (mean 11.7±7.2%).  
4.1.7 VLCD intervention 
In study II, population from very low calorie diet (VLCD) intervention study was included. 
It was a randomized clinical 1-year follow-up trial including individuals with mild 
obstructive sleep apnea. Study was conducted during October 2004 and December 2006. 
(348) The inclusion criteria were: (1) age 18–65 years; (2) BMI 28–40 kg/m2; and (3) apnea–
hypopnea index 5–15 events/hour. Serum ALT was used as the marker of liver disease in 
this study. Those 63 participants who had ALT and CK-18 measured before and after the 
intervention were included in the study II. Intervention group included 33 individuals, who 
received a 1-year lifestyle intervention including an initial weight reduction program with a 
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12-week VLCD of 600–800 kcal/day. Control group included 30 individuals, who received a 
single general dietary and exercise counseling session.  
 
Table 6. Clinical characteristics of the different populations used in this thesis (except in study II 
n=124 for KOBS). 
 
 
 
4.2 CLINICAL METHODS 
 
Body weight was recorded using a calibrated weighing scale and was measured with a 0.1 
kg precision. Height was measured to the nearest 0.1 cm. BMI was calculated as weight 
(kilogram) divided by height (meter) squared. Diabetes was defined by WHO´s criteria of 
diabetes (349). For study IV the respiratory quotient (RQ) (350) was calculated by dividing 
the CO2 eliminated by O2 consumed measured with indirect calorimetry (Deltatrac; Datex, 
Helsinki, Finland). The rate of lipid oxidation was calculated (g/min) with a simplified 
equation without urinary nitrogen: 1.81 x (O2 consumption – CO2 production). Metabolism 
of carbohydrates was calculated with a formula (4.12 x CO2 production) – (2.91 x O2 
consumption) (351).  
 
 
 
 
 
 KOBS 
 
(n=116) 
Helsinki-
Kuopio 
(n=296) 
Italians 
 
(n=380) 
D2D 
 
(n=2849) 
METSIM 
 
(n=8749) 
HEPFAT 
 
(n=56) 
VLCD 
 
(n=63) 
Sex (male-female) 39/77 116/180 246/134 1357/1492 8749 20/36 44/19 
Age (y) 47±9 47±9 48±12 6±8 57±7 55±9 52±9 
BMI (kg/m2) 45.1±6.1 43.7±8.6 31.7±8,4 27.5±4.8 26.8±3.8 30.8±3.5 32.6±3.0 
fP-insulin (mU/L) 19.9±12.0 17.0±11.0 20±21 8.8±16.4 8.35.9± 10.5±6.6 12.7±6.2 
Type 2 diabetes 
(%) 
41 39 20 17 0 15 - 
S-LDL cholesterol 
(mmol/L) 
2.5±0.9 2.5±0.8 3.2±1.0 3.4±0.9 3.4±0.9 3.3±0.8 2.9±0.8 
S-HDL cholesterol 
(mmol/L) 
1.1±0.3 1.2±0.4 1.3±0.4 1.4±0.3 1.5±0.4 1.4±0.3 1.1±0.3 
S-TGs (mmol/L) 1.6±0.7 1.6±0.9 1.6±1.4 1.4±0.8 1.4±1.0 1.4±0.8 1.7±1.1 
P-ALT (IU/L) 45±27 52±39 48±33 27±17 31±20 29±15 41±25 
P-AST (IU/L) 33±18 39±25 23±33 26±13 - - - 
NASH (%) 22 29 45 - - - - 
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4.3 LABORATORY METHODS 
 
4.3.1 Routine laboratory methods 
Plasma glucose was measured by enzymatic hexokinase photometric assay (Konelab 
Systems Reagents; Thermo Fischer Scientific, Vantaa, Finland). Insulin was determined by 
immunoassay (ADVIA Centaur Insulin IRI, no. 02230141; Siemens Medical Solutions 
Diagnostics, Tarrytown, NY). Cholesterol, HDL cholesterol and TG levels from the whole 
serum were assayed by standard automated enzymatic methods (Roche Diagnostics, 
Mannheim, Germany). LDL cholesterol was calculated using the Friedewald formula (352). 
Plasma ALT and AST concentrations were determined using kinetic International 
Federation of Clinical Chemistry methods (Roche Diagnostics, Mannheim, Germany). CK-
18 M30 antibody fragments (U/L) were measured with the Apoptosense® ELISA (cat.no 
10010) assay (PEVIVA AB, Sweden). Serum FFAs were analyzed by an enzymatic method 
from Wako Chemicals GmbH (Neuss, Germany). The adipose tissue IR index was 
calculated as FFA mmol/L x fasting plasma insulin pmol/L (353). 
 
4.3.2 PNPLA3 genotyping 
Genomic DNA was isolated from the blood mononuclear cells using the QIAamp DNA 
Blood kit (Qiagen, Hilden, Germany). The PNPLA3 rs738409 and TM6SF2 rs58542926 
polymorphisms were genotyped using an allele-specific PCR assay and a TaqMan probe 
(Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s protocols. 
 
4.3.3 Liver gene expression 
In studies III and IV, samples for gene expression were immediately frozen in liquid 
nitrogen. Total RNA from the liver tissue was extracted using Tri-Reagent (Applied 
Biosystems [ABI] Foster City, CA) and reverse-transcribed using the High Capacity cDNA 
Reverse Transcriptional KIT (ABI) according to the manufacturer´s protocol. Quantitative 
real-time polymerase chain reaction (PCR) was carried out with the Applied Biosystems 
7500 Real Time PCR System using KAPA SYBR FAST qPCR Universal Master Mix (KAPA 
Biosystems, Woburn, MA).  Relative expression was normalized to RPLP0.  
 
4.3.4 Serum and liver NMR analysis 
Fasting concentrations of lipoprotein subclass particles and their main lipid components as 
well as low-molecular weight molecules (LMWM) were analyzed by proton nuclear 
magnetic resonance (NMR) spectroscopy in native serum samples in studies III and IV (354-
356). The NMR data were measured at 37°C using a Bruker AVANCE III spectrometer 
operating at 500.36 MHz. The methodology is based on three different molecular windows, 
two of which (LIPO and LMWM) are applied to native serum and one for serum lipid 
extracts (LIPID).  
The LIPO window gives information, e.g., on the lipoprotein subclass distribution and 
lipoprotein particle concentrations for 14 lipoprotein subclasses. Fourteen lipoprotein 
subclasses were calibrated using high-performance liquid chromatography (357). The 
subclasses are as follows: chylomicrons and largest VLDL particles (average particle 
diameter at least 75 nm); five different VLDL subclasses: very large VLDL (average particle 
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diameter of 64.0 nm), large VLDL (53.6 nm), medium VLDL (44.5 nm), small VLDL (36.8 
nm), and very small VLDL (31.3 nm); intermediate-density lipoprotein (IDL) (28.6 nm); 
three LDL subclasses: large LDL (25.5 nm), medium LDL (23.0 nm), and small LDL (18.7 
nm); and four HDL subclasses: very large HDL (14.3 nm), large HDL (12.1 nm), medium 
HDL (10.9 nm), and small HDL (8.7 nm). The following components of the lipoprotein 
particles were quantified: phospholipids (PL), TG, and cholesterol. All of these components 
are not available for every subclass, because of the resolution issues (356). The VLDL 
cholesterol concentration was calculated by subtracting the LDL, IDL and HDL cholesterol 
from the total cholesterol. The total cholesterol content of chylomicrons and extremely large 
VLDL, very large VLDL and very small VLDL was calculated by subtracting the TG and 
phospholipid concentrations from the total lipids of each subclass. Lipid composition as a 
percentage of each available lipid of the total lipid content in each lipoprotein subclass was 
also calculated.  
The LMWM window gives information on various metabolites like amino acids and 
ketone bodies. The LIPID window gives information on various serum lipids like free 
cholesterol, esterified cholesterol and omega-3 fatty acids. This platform has been applied 
in various large-scale epidemiological and genetic studies (352,356,358)  
Liver free cholesterol content was analyzed from 45 individuals in study III. Liver 
samples (ca. 50 mg) were homogenized in 1.5 ml Eppendorf tubes in NaCl solution (150 µl 
of 150 mM NaCl in D2O) by pestle. After homogenization, 300 µl of CD3OD and 600 µl of 
CDCl3 were added and samples were mixed vigorously using a vortex mixer and sonicated 
15 min (indirect sonication) in an ice bath. After mixing, the samples were centrifuged 
(5000 x g, 10 min, 4°C) to separate the organic and water phase. The lower organic phase 
was recovered, and the aqueous layer was extracted again first with 600 µl and then with 
300 µl CDCl3 to standardize the yield. The separated organic layers were combined and 
evaporated to dryness under a gentle flow of dried air. Prior to NMR analysis, the extracted 
lipids were redissolved into 600 µl of CDCl3 containing 0.03% of tetramethylsilane as a 
reference substance. 
1H NMR spectra of extracted lipids were recorded on a Bruker Avance III HD 600 NMR 
spectrometer operating at 600.28 MHz and equipped with Prodigy TCI 5 mm cryogenically 
cooled probe head. Standard 1D 1H NMR spectra were recorded with 96k data points using 
32 transients and applying a standard Bruker zg pulse sequence. The acquisition time was 
5 s and the relaxation delay 15 s. The spectra were measured at 295 K. 
     For data processing, the free induction decays (FIDs) with 96k data points were zero-
filled to 256k data points and multiplied by an exponential window function with a 0.3 Hz 
line-broadening. The areas of the known lipid resonances (359) in the spectra were 
determined using a constrained total-line-shape fitting approach to enable quantitative 
analysis of severely overlapping peaks and to increase the quantification accuracy (354). 
This methodology allowed us to get information on the amounts of several lipid 
components in the extracted samples, e.g., free cholesterol and total TGs. The PERCH NMR 
software was used for all the lineshape fitting analyses. 
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4.3.5 Liver total cholesterol content measurement  
Total cholesterol content (per 100 mg liver tissue) was analyzed from 52 individuals in 
study III. It was quantified with gas-liquid chromatography (GLC) on a 50 m long capillary 
column (Ultra 2, Agilent Technologies, Wilmington, DE, USA) and 5α-cholestane was used 
as an internal standard (360).  
 
4.4 HISTOLOGICAL ASSESSMENT OF THE LIVER SAMPLES  
 
Liver biopsies were obtained using either Trucut needle (Radiplast AB, Uppsala, Sweden) 
or ultrasonic scissors during elective gastric bypass operation. Overall histological 
assessment of liver biopsy samples in KOBS was performed by one experienced pathologist 
according to standard criteria (6). Primarily, histological diagnosis was divided into 3 
categories: 1. not NASH, 2. possible NASH and 3. definitely NASH. According to the 
NASH clinical research networking scores and definitions (285) steatosis was graded into 4 
categories, fibrosis was staged from 0 to 4, and inflammation was defined as lobular 
inflammation (graded 0-3) (Table 7). Lobular inflammation was chosen as a marker of 
inflammation of liver because it was the most frequent inflammation variable. Subjects 
were also divided into categories based on clinical liver phenotype: 1. Normal liver without 
any steatosis, inflammation, ballooning or fibrosis, 2. simple steatosis (steatosis > 5%) 
without evidence of hepatocellular ballooning, inflammation or fibrosis, and 3. definite 
NASH (as described above). In studies III and IV 76 of 116 patients had clearly defined liver 
phenotypes (32 with normal liver, 19 with simple steatosis and 25 with NASH). In a study 
II, 82 of the 124 patients had a distinct liver phenotype (33 with normal liver, 20 with simple 
steatosis and 29 with NASH). Hemochromatosis was excluded by histological analysis of 
liver biopsies, and also by normal serum ferritin levels in subjects that had elevated serum 
ALT level. 
     In studies I and IV in Kuopio-Helsinki cohort liver histology was assessed by two 
experienced pathologists. They first analysed biopsies independently in a blinded fashion 
and after that together to obtain consensus. A 10% difference in fat content, 1 stage 
difference in fibrosis score or 1 grade difference in steatohepatitis activity was found in 15% 
of the samples. In Italian cohort (study I) liver histology was analysed by one experienced 
liver pathologist. In a study IV the liver phenotype was defined differently from KOBS 
population: Normal liver was defined when liver fat percent was <10% and there was no 
necroinflammation. In simple steatosis liver fat percent was >10% but there was no 
necroinflammation. NASH was defined as a combination of liver fat percent >10% with 
necroinflammation. 
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Table 7. Liver histology in different liver phenotypes (KOBS in studies III and IV). 
 
 Definition 
 
Score/code 
 
Normal Simple 
 
NASH 
   Liver steatosis  
 
 
  n=32 n=19 n=25 
Steatosis Grade     
 <5 % 0 32  0 0 
 5-33 % 1 0 15 10 
 33-66 % 2 0 2 10 
 >66 % 3 0 2 5 
      Location     
 Zone 3 0 9 11 12 
 Zone 1 1 0 1 3 
 Azonal 2 21 5 6 
 Panacinar 3 2 2 4 
 Microvesicular steatosis     
 Not present 0 31 13 11 
 Present 1 1 6 14 
Fibrosis Stage     
 None 0 32 19 4 
 Perisinusoidal or 
 
1 0 0 6 
 Mild, zone 3, 
 
1A 0 0 9 
 Moderate, zone 3, 
 
1B 0 0 1 
 Portal/periportal 1C 0 0 3 
 Perisinusoidal and 
 
2 0 0 1 
 Bridging fibrosis 3 0 0 0 
 Cirrhosis 4 0 0 1 
Inflammation Lobular inflammation     
 None 0 32 19 0 
  <2 foci per 200x field 1 0 0 17 
 2-4 foci per 200x field 2 0 0 8 
 >4 foci per 200x field 3 0 0 0 
 Microgranulomas     
 Absent 0 31 19 15 
 Present 1 1 0 10 
 Large Lipogranulomas     
 Absent 0 32 18 22 
 Present 1 0 1 3 
 Portal inflammation     
 None to minimal 0 32 19 21 
 Greater than minimal 1 0 0 4 
Liver cell Ballooning     
Injury None 0 32 19 9 
 Few balloon cells 1 0 0 12 
 many cells/prominent      
 
2 0 0 4 
 Acidophil bodies     
 None to rare 0 32 19 24 
 Many 1 0 0 1 
 Pigmented macrophages     
 None to rare 0 32 19 25 
 Many 1 0  0 0 
 Megamitochondria     
 None to rare 0 32 19 25 
 Many 1 0 0 0 
Other Mallory’s hyaline     
findings None to rare 0 32 19 24 
 Many 1 0 0 1 
 Glycogenated nuclei     
 None to rare 0 23 14 16 
 Many 1 9 5 9 
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4.5 STATISTICAL METHODS  
 
Characteristics of the study groups are given as means and standard deviations (SD). The 
unpaired t-test and the Kruskal-Wallis and Wilcoxon tests were used to compare normally and 
non-normally distributed data, respectively. The unpaired t-test with Bonferroni correction, 
when appropriate, was used to analyse intraindividual differences before and after surgery 
(false discovery rate = FDR). Chi-square test was used for analyzing categorical data. 
Spearman's rank correlation (studies III and IV) and Pearson's linear correlation (study II) were 
used for correlation analysis. All calculations were performed using SPSS 19.0 and 21.0 for 
Windows (SPSS, Chicago, IL) and the R 3.0.1 program (http://www.R-project.org, Vienna, 
Austria). Computational analysis of the NMR data was performed as described in NMR 
analysis chapter. GraphPad Prism 6 (GraphPad Software, Inc. La Jolla, California, USA) was 
used for drawing graphs. 
Development of the non-invasive scores was made as follows. In the study I the biopsy 
subjects were randomly divided into discovery (n=195) and validation (n=97) groups to build 
and validate the new scores. All study subjects with available data for the NASH score (n=292) 
were used as a second validation group. The unpaired t-test was used to compare the 
differences between the discovery and validation groups. Next, univariate logistic regression 
analyses were used to calculate odds ratios (OR) and confidence intervals (CI) for NASH. 
Multivariate logistic regression analyses were used to build the NASH score. Variables 
significantly associated with NASH in univariate logistic regression analyses were included in 
multivariate backward logistic regression analyses to identify variables independently 
associated with NASH. The receiver operator curve (ROC) and the Youden index (361) were 
used to estimate the optimal cut-off. The sensitivity, specificity, positive predictive values (PPV) 
and negative predictive values (NPV) for relevant cut-offs were calculated as described (362). 
For the NASH Liver Fat Score a new cut-off for NASH was calculated using the equation 
previously developed for diagnosis of NAFLD (363). The NAFLD Liver Fat Score was 
calculated as -2.89 + 1.18 × metabolic syndrome (yes=1/no=0) + 0.45 × type 2 diabetes 
(yes=2/no=0) + 0.15 × fS-insulin (mU/L) + 0.04 × AST (IU/L) – 0.94 × AST/ALT (363). A new cut-
off value was defined for NASH, and the score was named the NASH Liver Fat Score.  
In study IV, NASH predicting score was formed to find those with possible NASH in the 
METSIM study. First, the predictive value of age, weight, BMI, ALT, AST, bilirubin, alkaline 
phosphatase, INR, glucose, insulin, CK-18, β-OHB and serum FFAs was assessed with logistic 
regression for diagnosing NASH or ballooning in discovery cohort of 195 individuals in 
Helsinki-Kuopio biopsy cohort. First the association of these variables with NASH was 
evaluated with univariate logistic regression. Thereafter, variables that independently predicted 
NASH were identified by applying backward multivariate regression analysis. Fasting insulin, 
age and ALT remained in model to form a NASH finding score: -5.544 + 0.057 × age + 0.064 × 
fasting insulin + 0.014 × ALT.  
The performance of the scores was assessed by ROC curves. The area under the ROC-curve 
(AUROC) was used to describe the diagnostic accuracy of the scores. Sensitivity analysis in 
study I for calculated NASH score and the NASH Liver Fat score were performed by taking into 
account stochastic false-positivity and false-negativity rates in a Bayesian model. JAGS and R 
package (rjags) were used to construct the model on the basis of 2 Markov chains, each 
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containing 5000 ‘‘burn-in’’ samples and 10000 retained samples to obtain the posterior estimates 
of prevalence (364).  
 
4.6 APPROVALS 
 
Studies of this thesis follow the recommendations for biomedical research involving humans 
(Declaration of Helsinki of the World Medical Association 1964 including the revisions up to 
Hong Kong 1989 and Edinburgh, Scotland 2000) as well as a Finnish law concerning 
information protection. The KOBS project has been approved by the Ethics Committee of the 
Northern Savo Hospital District (54/2005,104/2008 and 27/2010). All methods have been 
previously used in humans and are known not to form any risk for the participants. The study 
population consist individuals who were eligible for obesity surgery and were willing to take 
part in the study. The nature and potential risks of the study were explained to all subjects 
before obtaining their written informed consent.  
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5 Results 
 
5.1 NON-INVASIVE SCORE FOR NASH (STUDY I) 
 
The main finding of study I was that easily accessible laboratory measurements such as serum 
AST and fasting insulin levels together with PNPLA3 rs738409 genotyping can be used to find 
those with NASH non-invasively. Furthermore, the prevalence of NASH in Finland was 
estimated for the first time.  
Development of NASH Score. Non-invasive score for NASH was formed by first analysing 
which variables were associated with NASH in a cohort of 296 bariatric surgery subjects in the 
Helsinki-Kuopio cohort (Table 8).  
 
Table 8. Odds ratios and confidence intervals of NASH in Helsinki-Kuopio cohort (OR = odds ratio, CI 
= confidence interval). 
 
Variables independently associating with NASH were put in logistic regression analysis. In the 
discovery cohort of 195 individuals, serum AST, PNPLA3 rs738409 genotype and serum fasting 
insulin level were strongest predictors of NASH forming the NASH Score. Based on these 
 All subjects  
OR (95% CI) 
P value Discovery 
cohort       
  
   
P value Validation 
cohort         
 
   
P value 
Age (years) 1.03 (1.01, 1.06) 0.02 1.04 (1.00, 1.07) 0.05 1.04 (0.99, 1.09) 0.15 
Gender 1.97 (1.18, 3.30) 0.01 2.0 (1.04, 3.83) 0.04 1.9 (0.81, 4.49) 0.14 
BMI (kg/m2)  0.98 (0.95, 1.00) 0.13 0.98 (0.94, 1.01) 0.22 0.97 (0.92, 1.02) 0.29 
Type 2 diabetes 1.87 (1.44, 2.44) <0.001 1.73 (1.24, 2.42) 0.001 2.10 (1.35, 3.33) 0.001 
Metabolic 
syndrome  
1.23 (0.65, 2.48) 0.54 1.31 (0.57, 3.28) 0.54 1.15 (0.40, 3.57) 0.80 
P-ALT (IU/l) 1.01 (1.00, 1.02) <0.001 1.01 (1.00, 1.02) 0.003 1.03 (1.01, 1.05) 0.001 
P-AST (IU/l) 1.03 (1.02, 1.05) <0.001 1.03 (1.02, 1.05) <0.001 1.04 (1.02, 1.08) 0.003 
fP-Insulin 
(mU/l) 
1.06 (1.04, 1.09) <0.001 1.06 (1.03, 1.10) <0.001 1.07 (1.02, 1.11) 0.004 
P-Albumin (g/l) 1.06 (1.00, 1.14) 0.06 1.07 (1.00, 1.17) 0.07 1.04 (0.91, 1.18) 0.60 
B-Platelets 
(x109/l) 
1.00 (0.99, 1.00) 0.08 1.00 (0.99, 1.00) 0.41 0.99 (0.99, 1.00) 0.06 
TGs (mmol/l) 1.28 (0.97, 1.69) 0.08 1.20 (0.86, 1.68) 0.27 1.51 (0.90, 2.63) 0.13 
S-HDL 
cholesterol 
 
0.86 (0.41, 1.66) 0.66 1.15 (0.48, 2.57) 0.72 0.48 (0.12, 1.57) 0.26 
S-LDL 
cholesterol 
 
1.08 (0.71, 1.65) 0.70 1.08 (0.64, 1.80) 0.78 1.06 (0.51, 2.24) 0.88 
S-CK-18 (U/L) 1.01 (1.00, 1.01) 0.001 1.01 (1.00, 1.01) 0.002 1.00 (1.00, 1.01) 0.21 
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variables, backward logistic regression analyses revealed a score best predicting NASH: -3.05 + 
0.562 x PNPLA3 genotype (CC = 1 / GC = 2 /GG = 3) – 0.0092 x fS-insulin (mU/L) + 0.0023 x AST 
(IU/L) + 0.0019 x (fS-insulin x AST). The AUROC of the NASH Score was 0.776 (95% CI: 0.701, 
0.852) in the discovery group. With optimal cut-off point -1.054 (determined with Youden index 
(361)), score had a sensitivity of 75% and specificity of 74% in the discovery group (Table 9). 
Next, the NASH Score was validated in the remaining 1/3 of Helsinki-Kuopio cohort (n=97) 
with AUROC of 0.758 (95% CI: 0.626, 0.891), and in the whole cohort and AUROC 0.774 (95% 
CI: 0.709, 0.839) (Figure 7), respectively. In the validation cohort sensitivity was 65% and 
specificity 73%, and in the whole cohort sensitivity was 72% and specificity 74% for predicting 
NASH (Table 9). Interestingly, the AUROC for CK-18 was 0.727 (95% CI: 0.660, 0.790) in the 
whole Helsinki-Kuopio cohort.  
Furthermore, a previously developed NAFLD Liver Fat Score (363) was tested in the 
prediction of NASH using a newly estimated cut-off (2.122). This NASH Liver Fat Score had an 
AUROC of 0.734 (95% CI: 0.664, 0.805) in the whole Helsinki-Kuopio cohort (Figure 7).  
Validation of the NASH Score. To further test developed NASH scores, they were validated in 
an Italian cohort consisting 380 moderately obese individuals. The NASH Score had AUROC of 
0.759 (95% CI: 0.711, 0.807) with a sensitivity of 39% and specificity of 89% (Table 9). The NASH 
Liver Fat Score had AUROC of 0.737 (95% CI: 0.687, 0.787) (Figure 7) with sensitivity of 93% and 
specificity of 33%. After the validation, scores were utilized to estimate the prevalence of NASH 
in Finnish adults in the D2D cohort. Scores were used in D2D study population (n=2849). 
Prevalence of NASH based on NASH Score and NASH Liver Fat Score were 4.2% and 6.0%, 
respectively. Because the accuracy of the developed scores was rather good, but not excellent, 
sensitivity analyses were made using a Bayesian model. Model gave estimates of 3.1% (NASH 
Score) and 3.6% (NASH Liver Fat Score) for the prevalence of NASH. Finally, based on the 
primary and Bayesian analyses, the prevalence of NASH in Finnish 45-74 year old subjects was 
estimated to be approximately 5%. 
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Table 9. Comparison of the performances of the NASH score with a cut-off -1.054 in the Helsinki-
Kuopio cohort (n=296) and in the Italian cohort (n=380). 
 
 
 
 
 
 
 
 
Figure 7. Comparison of NASH Score and NASH Liver Fat Score in Helsinki-Kuopio cohort (A) and in 
Italian validation cohort (B). 
 
 
 
 
 
 
 
Population AUROC (95% CI) Sens.% Spec.% 
Finnish biopsy cohort    
Discovery cohort 0.776 (0.701, 0.852) 75 74 
Internal validation 0.758 (0.626,0.891) 65 73 
Whole study group 0.774 (0.709, 0.839) 72 74 
Italian validation cohort    
Whole study group 0.759  (0.711,0.807) 39 89 
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5.2 SERUM CK-18 AS A MARKER OF NASH IN INTERVENTIONS (STUDY II) 
 
The main finding of study II was that serum CK-18 can be used for the screening of NASH in 
high-risk individuals, but it is not useful as a marker of intervention effect on NAFLD when the 
predicted probability of NASH is low. 
KOBS. Serum CK-18 M30 fragments correlated with serum ALT and AST levels (r = 0.347, P = 
9.2x10-5 and rs = 0.695, P = 1.1x10-14; respectively), and also with liver steatosis, inflammation and 
fibrosis (r = 0.348, P = 7.7x10-5; r= 0.377, P = 1.6x10-5 and r = 0.210, P = 0.019; respectively) in the 
KOBS cohort. The concentration of serum CK-18 was significantly higher in those with NASH 
(284 ± 161 U/L in those with normal liver, 331 ± 200 U/L in those with simple steatosis and 554 ± 
498 Ul/L in those with NASH, P = 0.004). CK-18 was also higher in those with NASH when 
pairwise compared to those with normal liver and also those with simple steatosis (P < 0.05). 
CK-18 had AUROC of 0.668 (95% CI: 0.555-0.781) for finding NASH in the KOBS population. 
     The change in serum CK-18 concentration correlated with ALT change (r = 0.454, P = 3.9x10-6) 
and CK-18 concentration decreased significantly after obesity surgery in the whole KOBS 
population (376 ± 303 U/L vs. 218 ± 187 U/L, P = 4.3x10-15) (Figure 8). There was a significant 
decrease in CK-18 concentration in all liver phenotype groups: in normal liver (284 ± 161 vs. 
241± 167 U/L, P = 0.006), in simple steatosis (332 ± 200 U/L vs. 225 ± 145 U/L, P = 0.004) and in 
NASH (554 ± 498 U/L vs. 236 ± 298 U/L, P = 4.2x10-5) (Figure 9).  The largest decrease was in 
those with NASH (-31 ± 97%). The decrease in CK-18 was not explained by weight loss, because 
weight loss was equal in the study groups (-20 ± 9% in those with normal liver, -26 ± 7% and -25 
± 7% in those with NASH; respectively, P = 0.116). 
The TM6SF2 rs58542926 genotype (171) associated with the CK-18 change (r = 0.225, P = 
0.034) suggesting that carriers of E167K variant (CC vs. CT) had smaller decrease in CK-18 
concentration after the surgery (-24% vs. -3%, respectively, P = 0.035). However, there was no 
association between CK-18 change and PNPLA3.  
Diet intervention study. Serum CK-18 concentration was not different in HEPFAT study 
population before the intervention between n-6 PUFA and SFA groups (P = 0.431). Liver fat 
content measured with MRS correlated with serum CK-18 concentration (r = 0.317, P = 0.017) 
and serum ALT level (r = 0.183, P = 0.177) at baseline. Mean liver fat percent of the whole study 
group was 5.6 ± 6.6% and CK-18 concentration was 215 ± 230 U/L in those with low liver fat (< 
5%) and 263±211 U/L in those with high liver fat (≥ 5%) (P = 0.117). Serum CK-18 concentration 
did not change significantly in the PUFA group (P = 0.190) or in the SFA group (P = 0.914), but 
tended to be lower after the n-6 PUFA diet compared to the SFA diet (192 ± 175 mmol/L and 271 
± 325 U/L, respectively, P = 0.064). There was no significant effect of the diets on CK-18 
concentration in the subgroups with low and high liver fat content. However, there was a trend 
for increase in CK-18 after the intervention in those with high liver fat (P = 0.087). In addition, 
weight did not change significantly during the study (P = 0.210).  
VLCD intervention study. Because ALT level at baseline and the effect of the intervention on 
the liver fat were mild in the HEPFAT study, it was investigated how more effective VLCD 
intervention, known to decrease liver fat content (365), affects serum CK-18 levels. Study 
subjects lost weight in both study groups (16.5±6 kg and 1.7±4 kg at 3 months, and 10.7±6 kg 
and 2.4±6 kg at 12 months, respectively). In the VLCD group, CK-18 decreased significantly at 3 
months (352±144 U/L vs. 269±128 U/L, P = 0.003) and also at 12 months (352±144 U/L vs. 280±118 
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U/L, P = 0.029). In the control group serum CK-18 level decreased at 3 months (311±130 U/L vs. 
249±92 U/L, P = 0.007), but not at 12 months (P = 0.673). 
 
 
Figure 8. CK-18 levels before and after the intervention in the KOBS and in the HEPFAT study 
separately for the groups on PUFA and SFA diet. The Wilcoxon nonparametric test was used for 
statistical testing. 
 
 
 
Figure 9.  The change in CK-18 during the intervention in different study groups. The Wilcoxon 
nonparametric test was used for statistical testing. 
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5.3 LIPOPROTEIN SUBCLASSES ASSOCIATE WITH NASH INDEPENDENTLY 
OF STEATOSIS (STUDY III) 
 
The main finding of study III was that cholesterol of lipoprotein subclasses associate with 
NASH independently of simple steatosis. Total and LDL cholesterol were higher in individuals 
with NASH compared to those with simple steatosis in traditional serum sample analyses (P = 
0.002 and P = 0.007, respectively). The results were essentially same, when individuals using 
cholesterol lowering medication (n=21) were excluded. Steatosis grade associated with higher 
fasting insulin levels, but not with cholesterol levels. However, lobular inflammation and stage 
1 fibrosis associated with serum total and LDL cholesterol levels. There was no difference when 
comparing individuals without fibrosis to those with grade 2-4 fibrosis.  
 
Table 10. Clinical characteristics based on liver phenotype in the KOBS population (Study III and 
Study IV). Kruskal-Wallis test for continuous variables and Chi-Square test for categorical variables. 
#Normal liver vs. NASH P < 0.05, ▲Steatosis vs. NASH P < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal liver 
 
(n=32) 
Simple 
steatosis 
(n=19) 
NASH 
 
(n=25) 
P value 
over 
groups 
Sex (male-female) 11/21 4/15 10/15 0.404 
Age (y) 47.9 ± 9.7 45.8 ± 9.8 46.7 ± 8.0 0.725 
Weight (kg) 127.2 ± 19.4 126.2 ± 14.8 132.1 ± 24.5 0.676 
BMI (kg/m2) 44.1 ± 6.8 44.8 ± 4.3 44.3 ± 6.9 0.716 
Fasting glucose (mmol/L) 6.1 ± 0.9 6.3 ± 1.2 6.5 ± 1.6 0.929 
Fasting insulin (mU/L) 14.5 ± 9.0 19.7 ± 10.1 25.4# ± 17.1 0.006 
Type 2 diabetes (%) 8 (25) 6 (31) 11 (44) 0.257 
Total cholesterol (mmol/L) 4.23 ± 0.8 3.80 ± 0.9 4.74#▲ ± 1.0 0.004 
LDL cholesterol (mmol/L) 2.48 ± 0.7 2.11 ± 0.8 2.89▲ ± 1.0 0.010 
HDL cholesterol (mmol/L) 1.07 ± 0.3 1.02 ± 0.2 1.06 ± 0.4 0.539 
Total triglycerides (mmol/L) 1.49 ± 0.7 1.46 ± 0.6 1.74 ± 0.6 0.103 
ALT (IU/L) 40.6 ± 25.1 39.1 ± 15.9 56.8 ± 35.1 0.117 
AST (IU/L) 28.3 ± 10.1 28.7 ± 8.1 42.7 ± 30.1 0.066 
CK-18 455 ± 505 290 ± 185 362 ± 226 0.459 
PNPLA3 rs738409 (n) 
 
 
  
 
  
 
 
0.327 
CC 23 11 16  
CG 9 6 5  
GG 0 2 3  
43 
 
 
 
Figure 10. Serum lipid levels with traditional enzymatic method in individuals divided into groups by 
(A) steatosis (B) inflammation and (C) fibrosis. The Kruskal-Wallis test was used to assess 
differences among groups. 
 
Serum NMR analysis. NMR spectroscopy analysis (354,358) revealed that total lipid 
concentration of all VLDL (excluding very small VLDL) together with medium and small LDL 
associated with NASH (FDR < 0.1). The total lipid concentrations in VLDL, IDL and LDL 
subclasses (excluding very small VLDL) did not associate with steatosis, but associated with 
inflammation and grade 1 fibrosis. In more advanced fibrosis, lipoprotein lipid concentrations 
were lower than in grade 1 fibrosis (Figure 11). The total lipid concentration of all VLDL and 
LDL particles also had an association with both the NAFLD activity score and ballooning (FDR 
< 0.1).  
The cholesterol concentration of VLDL (except in small VLDL), IDL and LDL subclasses 
associated with inflammation and fibrosis (FDR < 0.05), but not with steatosis (Figure 12). 
Interestingly, association of cholesterol concentration of large, medium and small VLDL, and 
large and medium LDL with liver inflammation was independent of steatosis, total TGs and 
fasting insulin (all P < 0.05)  
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Figure 11. Lipoprotein subclass lipid concentration in individuals divided into groups by (A) liver 
phenotype, (B) steatosis grade, (C) lobular inflammation and (D) fibrosis stage. Percentage changes 
comparing to the group without the pathology (set to 0%) have been calculated. Statistical 
significance over all groups (normal and all degrees of pathology in each panel) are visualized with 
*= false discovery rate (FDR) < 0.05 and # = FDR < 0.01 compared to individuals without the 
pathology below the horizontal axis in each panel. Color of the symbol (white, gray, black) indicates 
subgroup analysis comparing given group to the group without pathology (gray indicates P < 0.05, 
black P < 0.01).  
 
Figure 12. Lipoprotein subclass cholesterol content in individuals divided into groups by (A) steatosis 
grade, (B) inflammation and (C) and fibrosis stage. Description of symbols is similar to Figure 9. 
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Lipoprotein subclasses and liver cholesterol content. Liver total cholesterol content correlated 
positively with lobular inflammation (rs = 0.393, P = 0.004), but not with steatosis (rs = 0.258, P = 
0.065) or fibrosis (rs = -0.186, P = 0.221). Liver total cholesterol content (n=52) correlated with 
subclasses of VLDL cholesterol, but not with LDL and HDL cholesterol (Figure 13). Liver free 
cholesterol content (n=45) correlated with liver total cholesterol content (rs = 0.419, P = 0.024), 
but not with steatosis, lobular inflammation or fibrosis. Furthermore, liver free cholesterol 
content correlated with cholesterol of all VLDL subclasses (rs = 0.315-0.381, P < 0.005) except 
with small VLDL (rs = 0.279, P = 0.063), but not with LDL and HDL cholesterol (Figure 13). 
 
Figure 13. (A) Lipoprotein subclass cholesterol concentration in individuals with NASH compared to 
those with normal liver. Percentage changes comparing to the group without the pathology (set to 
0%) have been calculated and color of the symbol indicates subgroup analysis comparing given 
group to the group without pathology (gray indicates P < 0.05, black P < 0.01). Spearman 
correlation between lipoprotein subclass cholesterol concentration and liver cholesterol content (B), 
and liver free cholesterol content (C) (black bars P < 0.05). 
Gene expression in the liver. Because high VLDL cholesterol is linked with increased cholesterol 
synthesis in the liver (137), liver mRNA expression of genes regulating cholesterol synthesis and 
uptake was measured. These genes did not correlate with liver histology (all P > 0.3) and had 
only some correlations with different lipoprotein cholesterols. However, XBP1 splicing 
correlated with lobular inflammation (rs = 0.272, P = 0.014) and ballooning (rs = 0.243, P = 0.029), 
but not with steatosis (rs = 0.080, P = 0.479). XBP-1 splicing also associated with cholesterol 
concentration of small VLDL, IDL, LDL subclasses and medium HDL (rs = 0.220-0.313, P < 0.05).  
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5.4 LIPID OXIDATION AND ALTERED KETONE BODY METABOLISM IN NASH 
(STUDY IV) 
 
The main finding of study IV was that individuals with NASH had lower ketone body levels 
and altered ketone body metabolism.  
Levels of ketone bodies β-OHB and AA were significantly different between study groups (P 
= 0.011 and P = 0.017, respectively), and they were lower in individuals with NASH compared 
to those with simple steatosis (P = 0.004 and P = 0.018, respectively) (Figure 14). However, there 
was no difference between those with normal liver and those with simple steatosis (P = 0.106 
and P = 0.267, respectively). Levels of ketone bodies also associated with liver cell ballooning (P 
= 0.0005 for β-OHB and P = 0.0003 for AA), but interestingly not with steatosis and fibrosis. 
Both β-OHB and AA levels correlated with negatively with RQ (rs = -0.614, P = 0.001 and rs = -
0.615, P = 0.001; respectively) and had a positive correlation with the rate of lipid oxidation (rs = 
0.663, P = 0.0004 and rs = 0.688, P = 0.002; respectively). Serum citrate levels had a similar trend 
to ketone bodies. Citrate levels were lower in those with NASH than in those with normal liver 
(P = 0.009), or simple steatosis (P = 0.007).  However, other energy metabolism-related LMWMs 
(like lactate and pyruvate) were not different between study groups. 
 
Figure 14. Levels of ketone bodies β-hydroxybutyrate (A) and acetoacetate (B) differed between the 
study groups (KOBS) and were lower in individuals with NASH than in those simple steatosis. Lipid 
oxidation had a positive correlation with β-hydroxybutyrate levels (C). Serum citrate levels were 
lower in individuals with NASH than in individuals with steatosis or normal liver. Asterisk denotes a P 
value < 0.05 (Kruskal-Wallis test). 
Replication of the primary results. Finding of lower β-OHB levels was validated in the Helsinki-
Kuopio cohort (study I). β-OHB was measured with an enzymatic method in 188 individuals 
with an overlap of 56 individuals from the KOBS cohort. β-OHB tended to be lower in 
individuals with steatosis combined with necroinflammation than in those with simple steatosis 
(P = 0.060). When normal weight individuals (BMI under 25 kg/m2) were excluded, the 
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difference was statistically significant (n = 185 and P = 0.041). The result was also validated in 
the METSIM population-based study. The non-invasive NASH Score developed in this thesis 
found 5086 individuals below the cut-off and 3585 individuals above the cut-off, meaning 
possible NASH. β-OHB levels were lower in those below the cut-off (0.137 vs. 0.129 mmol/L, P = 
0.001) (Figure 15). 
 
Figure 15. Ketone body levels in the Helsinki-Kuopio cohort (A) and in the METSIM population study 
population (B). The Kruskal-Wallis test was used to assess differences among groups. 
FFAs and ketone bodies. Serum fasting FFAs correlated positively with β-OHB and AA (rs = 
0.559, P = 6.9x10-11 and rs = 0.452, P = 3.5x10-7, respectively). They were also lower in NASH than 
in simple steatosis (0.74 vs. 0.55 mmol/L, P = 0.030). In multivariate logistic regression analysis, 
the predictive value of age, weight, BMI, ALT, AST, bilirubin, alkaline phosphatase, INR, 
fasting glucose, fasting insulin, CK-18, β-OHB and serum fasting FFAs in diagnosing NASH or 
ballooning was tested. After backwards logistic regression, β-OHB remained in the model, 
suggesting that it was the strongest independent predictor of NASH. 
Gene expression in the liver. Liver gene expression of lipid and ketone body metabolism 
associated genes revealed that β-OHB and AA correlated negatively with SREBP-1c (rs = -0.318, 
P = 0.004 and rs = -0.308, P = 0.005; respectively). Both β-OHB and AA had a negative correlation 
with fatty acid synthase (FASN) (rs=-0.355, P=0.0009 and rs=-0.382, P=0.0003; respectively).  
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Figure 16. Genes in liver metabolism analysed in study III. Dashed arrows mark the direction of the 
change in metabolic pathways associated with NASH. TCA = tricarboxylic acid cycle. 
Because lower FFA supply did not explain the lower ketone body levels in NASH, liver gene 
expression of genes regulating fatty acid synthesis, fatty acid oxidation, ketogenesis and 
ketolysis was analysed (Figure 16). There were no differences between liver phenotype groups 
in genes regulating fatty acid oxidation and ketogenesis. However, expression of ketolytic genes 
(ACAT1 and BDH1) was higher in NASH. Furthermore, expression of ACAT1, ACSS2 and 
BDH1 correlated positively with lobular inflammation (rs = 0.388, P = 0.0003, rs = 0.379, P = 
0.0006 and rs = 0.385, P = 0.0004, respectively), but interestingly not with steatosis and fibrosis. 
Liver gene expression of ACAT1 had also a positive correlation with ballooning (rs = 0.262, P = 
0.018). 
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6 Discussion 
 
6.1 PATIENTS AND METHODS 
6.1.1 Study design and subjects 
The KOBS cohort was the primary study population in this thesis. It had over 100 well 
characterized subjects with detailed liver histology. Individuals in KOBS cohort had clinical and 
laboratory measurements taken at baseline and one year after surgery. This cohort provided 
large prospective study population to investigate metabolic changes associated with NASH. In 
addition, control measurements one year after the operation provided option to investigate 
changes associated with the improvement in liver disease. Individuals in KOBS were severely 
obese and thus observed results may not be generalized to normal weight subjects. However, 
obesity is a strong risk factor for NAFLD (1,2), and thus the KOBS cohort was an optimal 
population for studying NAFLD. However, NAFLD can be present also in lean individuals 
(133), and PNPLA3 genotype at rs738409 is strongly associated with NAFLD in lean subjects 
(157). The association of PNPLA3 with NASH would optimally be investigated in a cohort 
including both normal weight and obese individuals. This should be considered in the future, 
although it is challenging to justify taking liver biopsies if there is no suspicion of NASH. 
The KOBS cohort has some limitations. First, there is no control group of lean individuals. 
However, characterization of different liver phenotypes gave an opportunity to compare results 
within the same BMI range. Furthermore, it should be kept in mind that the primary focus of 
these studies was liver disease. Unfortunately, follow-up liver biopsy was available only from 
11 individuals. However, obesity surgery is known to ameliorate NASH (70,71,311-313). 
Second, the majority (108 of 116) of the patients had VLCD 4 weeks before the operation. This 
could have affected the results, especially in the study IV. A VLCD diet is essential before the 
obesity surgery to decrease the liver fat content. In addition, 21 out of 116 individuals had 
cholesterol lowering medication (statin), which regulate cholesterol metabolism. Importantly, 
results in the study III were essentially same if those having statin treatment were excluded. 
Some measurements in KOBS cohort were not available from all study subjects. Indirect 
calorimetry was measured only in 15 individuals (5 with normal liver and 10 with NASH). 
However, when rates of lipid oxidation and metabolism of carbohydrates were calculated, 
clearly statistically significant results were achieved. Furthermore, liver total and free 
cholesterol were analysed in a limited number of subjects (n=52 and n=45, respectively) in the 
KOBS. Limited sample size might have had an effect on results. However, sample numbers are 
higher than (210) or similar to (224) previous studies.  
The Helsinki-Kuopio cohort was a larger cohort including 89 individuals from the KOBS 
cohort. Subjects in the cohort had all the essential variables measured for the development of 
the non-invasive score. The majority of individuals in the Italian cohort have had liver biopsy 
because of persistently abnormal liver enzymes, representing real-life patients. CK-18 
measurement was not available in the Italian cohort. Because CK-18 did not remain in the 
NASH Score, it was not essential. However, it would have been interesting to test the ability of 
50 
 
 
CK-18 for diagnosing NASH in a big Italian cohort. The Italian cohort subjects were only 
moderately obese, which can be considered a limitation when comparing to a severely obese 
primary cohort. However, the NASH Score proved to perform equally well also in Italian 
cohort.  
D2D and METSIM study offered big, well characterized populations with comprehensive 
data to validate primarily observed results. Genotyping of PNPLA3 at rs738409 in the D2D 
population gave an excellent opportunity to use the NASH Score in this cohort and evaluate the 
prevalence of NASH in Finland for the first time. The D2D and METSIM population based 
studies had mainly slightly overweight individuals, which can limit the comparability of their 
results with the results of the KOBS. However, these populations were used as validation and 
replication cohorts to strengthen observed results. ALT was used as a marker of liver disease in 
METSIM population. Because ALT is not optimal marker of NASH (89), non-invasive score was 
formed to find those with NASH. Unfortunately, AST was not measured in these individuals 
and thus the NASH score from study I could not be used.  
The HEPFAT study was a randomized, parallel-group study. However, it was a quite small 
study with 67 individuals, and only 56 individuals had all measurements needed in study IV. In 
addition, the 10 week intervention was rather short to cause large changes. Nonetheless, it was 
a well conducted randomized study that demonstrated that dietary fatty acid composition has 
an effect on liver fat. HEPFAT study subjects were moderately obese (BMI 31) and those with 
BMI >40 were excluded from the study. Additionally, their mean liver fat content was only 5.6 ± 
6.6%. Thus, it is probable that study subjects had mainly steatosis and not NASH. However, 
liver fat content decreased in HEPFAT trial (305), and thus measuring the change in CK-18 was 
justified. Low ALT and low liver fat content in HEPFAT study subjects might reflect lack of 
NAFLD and could explain the small change in CK-18 levels in response to the intervention. 
Thus, an additional VLCD study cohort with higher baseline ALT was included in the study II. 
 
6.1.2 Clinical measurements and laboratory methods  
Indirect calorimetry was used as an estimate of the energy expenditure based on oxygen 
consumption and carbon dioxide excretion. Direct measurement is not possible and indirect 
calorimetry is the best way to measure the energy consumption in clinical populations (366). 
Standardized and validated laboratory methods for blood sample analyses were used. NMR 
spectroscopy has been already applied in various large-scale epidemiological and genetic 
studies (367,368), and it has been proven to quantify serum lipids and lipoproteins reliable and 
cost-effectively (356). The main advantage of NMR spectroscopy is to measure several different 
particles in a single sample rapidly (356). This method offers a hypothesis-free approach to find 
associations in epidemiological studies. However, in the studies of this thesis, NMR 
spectroscopy was used as a normal laboratory measurement in a hypothesis driven fashion. 
NMR spectroscopy offered an optimal method to investigate lipoprotein lipid profile in those 
with NASH. 
Liver biopsies offered unique opportunities also for analyses other than standard histological 
evaluation. These included liver gene expression, which gave essential information about 
metabolic pathways when combined with other results. Furthermore, possibility to measure 
liver total cholesterol content gave deeper understanding about cholesterol metabolism in those 
with NASH. Importantly, in study IV NMR spectroscopy was used to quantify liver cholesterol 
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content. NMR has been rarely used for that purpose and measurement was obvious strength in 
this thesis, because liver free cholesterol is strongly associated with NASH (210,228,230). 
Method for liver NMR cholesterol analysis was developed for this thesis and thus has not been 
validated before. However, total cholesterol measured with NMR had excellent correlation with 
the results from the GLC measurement. 
Estimation of insulin sensitivity was based on levels of fasting insulin, which can be thought 
of as a non-optimal method. The hyperinsulinemic-euglycemic clamp has been considered as 
the gold standard for assessing insulin action in vivo. However, fasting insulin levels have a 
moderately high correlation with results achieved with the clamp and are widely used as a 
crude measure of insulin resistance (369). 
 
6.1.3 Diagnosis of NASH 
In the studies of this thesis, liver biopsy was used for diagnosing NASH. Liver biopsy is a gold 
standard for the diagnosis of NASH (295) and thus the optimal method was used. However, 
liver biopsy presents only a small amount of the liver, which makes limitations for histological 
analysis. Nonetheless, a better option for diagnosis is not available and multiple biopsies are 
usually not done, because of the risk of complication (294). Because liver biopsy analysis is 
pathologists dependent (295), in these studies a maximum of two pathologists per study were 
used to evaluate liver biopsies. The histological characterization was different in the Helsinki-
Kuopio biopsy cohort and therefore the results cannot be directly compared to those with KOBS 
(study IV). A limitation of the population-based studies is that liver biopsies were not available. 
However, it is ethically impossible to obtain liver biopsies in population-based studies.  
 
6.2 NON-INVASIVE SCORE TO FIND NASH (STUDIES I AND II)  
 
Non-invasive NASH Score was carefully developed and validated and is one of the few, which 
have been both internally and externally validated (267). External validation is essential, before 
real benefits of the score can be evaluated. Study I gave novel information about the prevalence 
of NASH in Finnish adult subjects. Since NASH score worked equally well in Italian validation 
cohort, the prevalence estimate could be generalized for Europeans with a similar range in age 
and BMI. Results of study I are very important, because previous prevalence estimates of 
NASH are based on selected groups of patients (1,111,114-117,370,371) suggesting that their 
results cannot be generalized to the standard population. Results from study I suggest that 
NASH is very common disease. Since it increases both mortality and morbidity, more attention 
should be paid to decrease the prevalence of the main risk factor, obesity. Interventions should 
be focused also for adolescents and importantly even before individuals are obese. Based on the 
estimated prevalence, NASH will be more common reason for liver transplantation in the 
future also in Finland (132). Alcohol has been the major cause for liver cirrhosis in Finland (372). 
Nonetheless, it is probable that obesity together with high alcohol consumption causes liver 
injury earlier than each alone (373). 
The development of the NASH Score revealed that easily available AST is one of the best 
routine markers to find NASH. AST might have been used too sparingly in Finnish health care 
system in recent years. Although transaminases might be normal in those with NASH (89), AST 
measurement should be considered when taking liver enzymes in obese individuals. In 
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addition, PNPLA3 at rs738409 associated with the risk of NASH like previously published (157). 
PNPLA3 genotyping option should be available more widely than it is today. It would help to 
plan follow-up for patients with NAFLD, because carriers of G/G genotype are at risk for more 
severe disease (167). Additionally, genotyping could strengthen the diagnosis when lean 
individual is having NAFLD.  
The NASH Score is not accurate enough for being a diagnostic tool. It had a good, but not 
excellent AUROC (0.774) for finding NASH. However, the NASH Score could help to find 
patients with possible NASH when considering liver biopsy. Secondly, NASH Score could be 
used in population-based studies where liver biopsies cannot be obtained. The limitation for the 
NASH score use is that PNPLA3 genotyping is not widely available, and insulin measurements 
have not been standardized. The AUROC of the NASH score was similar to that of other 
NASH-predicting tests in a meta-analysis of 494 severely obese individuals (279), but slightly 
worse than the Nice model (components CK-18, ALT and metabolic syndrome) (271). However, 
the Nice model has not been validated externally. Scores that have had good or excellent 
AUROCs (112,268,270,275) have small study populations, and have not been externally 
validated.  
Results from study I and II suggest that CK-18 is a good, but not optimal biomarker for 
detecting NASH. Interestingly, CK-18 did not remain in the NASH Score (study I), even though 
it had an AUROC almost as high as the NASH Score (0.727). This might be because of the high 
standard deviation of values. The results suggest that CK-18 cannot be used as a diagnostic tool, 
but it could help as a screening method (260). With a low cut-off it could be used to screen for 
fatty liver, and with a higher cut-off to screen fibrosis (264). Option for CK-18 measurement 
would help in clinical decision-making, when considering the possibility of NASH. However, 
based on findings from study II, CK-18 is not useful as a marker of intervention effect for the 
liver if the predicted probability of NASH is low (low liver fat content) or the intervention effect 
on the liver is modest. Finally, it should be highlighted that the need for optimal biomarker is 
obvious. However, as long as the pathogenesis of NASH is unclear, it will be difficult to find an 
optimal biomarker for NASH.  
 
6.3 LIPOPROTEIN SUBCLASSES ASSOCIATE WITH NASH INPENDENTLY OF 
STEATOSIS (STUDY III) 
 
Study III supported the idea about the importance of cholesterol metabolism in NASH. 
Previously reported association of cholesterol metabolism with simple steatosis (13,137) and 
NASH (210,211) was further clarified. The major finding was the association of liver 
inflammation and lipoprotein subclass cholesterol independent of liver steatosis, TGs and 
fasting insulin.  
Liver free cholesterol accumulation has been suggested to be a key factor in NASH causing 
mitochondrial stress (243,244), but it has still been limitedly studied in humans with NASH 
(210,224,228). In study III, liver total cholesterol content correlated with liver inflammation. 
Liver free cholesterol content correlated with liver total cholesterol, but not with liver steatosis, 
inflammation or fibrosis. However, liver free cholesterol content was associated with 
cholesterol concentration of majority of VLDL subclasses. This suggests that liver free 
cholesterol content reflects increased cholesterol synthesis, but does not support its individual 
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role in NASH (230,243). Nonetheless, this may be because of limited number of free cholesterol 
measurements in this study (n=45) and should be studied further.  
Interestingly, the expression of cholesterol synthesis genes did not associate with steatosis, 
inflammation, or fibrosis. This suggests that increased cholesterol synthesis does not explain the 
role of cholesterol and its accumulation in NASH. However, liver gene expression of XBP1 
splicing associated with liver inflammation and ballooning, but not with steatosis. It also 
associated with the cholesterol concentration of small VLDL, IDL, LDL subclasses and medium 
HDL. XBP1 splicing takes part in liver lipid metabolism (203) and has a role in ER stress in the 
liver (204). ER stress can cause liver steatosis (200), further disturb ER function (18) and 
promote liver injury. Upregulation of XBP1 splicing may have a crucial role in starting this 
cycle. 
Results from study III support previous findings that non-HDL cholesterol (VLDL+LDL) has 
been associated with NASH (374). It seems improbable that cholesterol subclass panel would 
work as a biomarker of NASH, because cholesterol levels vary widely also without NASH. 
However, the possible benefits of NMR lipidomics panel for finding NASH should be studied 
in a larger human population. 
Finally, also based on results of study III, drug therapy focusing on cholesterol metabolism in 
NASH needs urgently more research. There are already studies about the benefits of statins 
(332,333), and some data about the ezetimibe treatment (334). The combination of statin and 
ezetimibe (blocking cholesterol synthesis and absorption) should be investigated, although 
cholesterol absorption is reported to be decreased in NAFLD (211). In addition, the possibility 
that PNPLA3 I148M genotype limits the effect of statins on steatosis and NASH (333) should be 
further studied. 
 
6.4 LIPID OXIDATION AND ALTERED KETONE BODY METABOLISM IN NASH 
(STUDY IV)  
 
The most important finding from study IV was that serum ketone body levels (AA and β-OHB) 
were lower in NASH than in simple steatosis. This suggests altered ketone body metabolism in 
those with NASH. Previously, lipid oxidation rates in NAFLD has been controversial (16,21-24). 
Based on the levels of ketone bodies in study IV, oxidative metabolism is possibly increased in 
those with simple steatosis, but significantly decreased in those with NASH. Observed decrease 
in lipid oxidation (21) suggests mitochondrial dysfunction in NASH (20). Mitochondrial 
dysfunction could result from the changes in cholesterol metabolism. Possible reasons may be 
increased cholesterol synthesis and cholesterol accumulation (study III) and altered trafficking 
in the liver cell, leading to ER stress. This could further lead to free cholesterol accumulation in 
the liver and especially in the mitochondria (228,243,244). If mitochondrial oxidative function 
declines, also fatty acids can accumulate and cause lipotoxicity and NASH progression (180).  
Decreased oxidative metabolism was further supported by decreased citrate levels in NASH. 
Lower citrate levels might be caused by less substrate for the TCA cycle, meaning decreased 
amounts of Acyl-CoA from β oxidation. Thus, ketone body levels might decrease, because 
ketolysis may compensatorily increase to provide more Acyl-CoA for TCA cycle. This was 
supported by overexpressed ketolysis genes ACAT1 and BDH1 in the liver of those with NASH.  
54 
 
 
Based on the results from study IV, ketone body levels cannot be considered biomarkers of 
NASH, because they seemed to be increased in simple steatosis (Helsinki-Kuopio cohort), but 
decreased in NASH. It would therefore be difficult to separate those with normal liver from 
those with NASH. However, ketone body measurement in those with fatty liver may be helpful 
revealing the development of higher grade inflammation. Thus, further studies about this 
subject are urgently needed. The possibility if ketone bodies and citrate levels could be used as 
biomarkers of NASH (maybe together with serum CK-18) should be considered.  
Finally, drug development in NASH should be addressed for protection of mitochondrial 
function. There are already data from a study in mice suggesting that mild mitochondrial 
uncoupling reverses diabetes and NASH (375). However, data about cholesterol toxicity (study 
III) and cholesterol-associated mitochondrial disturbances (228,243,244) in NASH suggest that 
cholesterol metabolism should perhaps be the primary treatment target. 
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7 Conclusions 
 
The main findings and conclusions of these series of studies were: 
 
I PNPLA3 rs738409 genotype together with routine laboratory tests could be used as 
a non-invasive method for screening NASH. The prevalence of NASH based on this 
screening in Finnish adults is approximately 5%. 
 
II CK-18 could be used as a biomarker of NASH, if the predicted probability of the 
disease is high.  
 
III  Cholesterol metabolism is associated with the development of NASH 
independently of simple steatosis.  
 
IV Lipid oxidation is decreased in NASH, suggesting mitochondrial dysfunction. 
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8 Future Perspectives 
 
Serum CK-18 has been suggested as a screening tool for NASH (261-263), although its 
sensitivity to distinguish simple steatosis from NASH has been questioned (264). Studies of this 
thesis support those findings. However, the potential of CK-18 as a biomarker of NASH needs 
to be studied further. Because an optimal biomarker for NASH is still undiscovered, additional 
studies about biomarkers are urgently needed. 
There are two interesting genotypes associated with NASH: PNPLA3 rs738409 (157) and 
TM6SF2 rs58542926 (168). Study II suggests that TM6SF2 variant carriers may have smaller 
decrease in CK-18 after the surgery. Thus, it is important to investigate if the effect of obesity 
surgery on NASH differs based on NASH risk genotypes. Additionally, it should be studied if 
the usefulness of CK-18 for finding NASH depends on NASH associated genotypes.  
Although the pathogenesis of NASH is still not thoroughly understood, cholesterol 
metabolism is strongly associated with the process (14,210,211,228). However, it is not totally 
clear if the changes in cholesterol metabolism (for example increased cholesterol synthesis and 
accumulation) are causes or consequences of NASH. Previously non-HDL cholesterol (374) and 
desmosterol (212) have been suggested as biomarkers of NASH. Further investigation of 
cholesterol metabolism in NASH should be given top priority. High quality studies are very 
likely to find more biomarkers of NASH.  
Previously the role of free cholesterol in NASH has been studied combining liver gene 
expression analyses with cholesterol content measurements (224). However, there is an urgent 
need to find the primary mechanism for free cholesterol accumulation in the liver. This requires 
careful investigation of cholesterol uptake, synthesis, trafficking and excretion pathways in the 
liver together with other possible changes in liver lipid content. Furthermore, a study with 
follow-up liver biopsies with liver lipid content analysis would be highly valuable. It would 
help to figure out what liver lipids at baseline are associated with more advanced NASH in the 
follow-up. In addition, other lipids in the liver should be investigated in more detail. These 
include for example phosphatidylcholines, which are reported to be decreased in the liver of 
those with steatosis (210,376). Our preliminary data suggests that serum phosphatidylcholines 
are increased in those with NASH, but phosphatidylcholine content in the liver is decreased in 
those with NASH. 
Although NAFLD and NASH are strongly associated with the metabolic syndrome (44), the 
PNPLA3 rs738409 genotype associated NAFLD does not have similar metabolic abnormalities 
(79), suggesting lower risk for cardiovascular complications. Moreover, the TM6SF2 rs58542926 
genotype is associated with increased liver fat content (170) and increased risk of NASH (171), 
but decreased risk for cardiovascular disease (171). Metabolomic approach could be used to 
find metabolical differences between risk genotypes. In addition, subjects with these risk 
variants could be screened from the population-based study (such as METSIM) to be further 
evaluated. Examination including liver fat content measurement or liver biopsies (risk variant 
carriers are at increased risk for NASH) together with serum and liver NMR analyses could 
reveal differences in energy and cholesterol metabolism based on the risk genotypes. 
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New treatment options for NASH are needed to ameliorate liver disease and avoid 
cardiovascular complications. Understanding free cholesterol accumulation and the 
disturbances in mitochondria have great potential to lead to new clinical solutions in the 
treatment of NASH. Since mitochondrial dysfunction has critical role in NASH, restoring 
mitochondrial function is essential in the treatment of NASH. Furthermore, mitochondrial 
transplantation has been done in animal models in cardiac ischemia (377), and transplantation 
of autologous mitochondria could help in NASH reversion. Interestingly, administration of β-
OHB has been shown to prevent PUFA-induced acute liver failure in an experimental animal 
model (378). In addition, ketone body supplementation decreases mitochondrial production of 
ROS in the brain (379). Thus, the administration of ketone bodies and normalization of ketone 
body metabolism should be tested as a treatment option of NASH. When disturbances of 
cholesterol metabolism in those with NASH are better understood, also gene therapy options 
(for example LDLR overexpression (380)) could be tested. Finally, human hepatocyte 
transplantations have already been made in treatment of the Crigler-Najjar syndrome (381), and 
this approach should be studied further. 
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Non-alcoholic steatohepatitis (NASH) 
is a common cause of chronic liver 
disease. However, pathogenesis of 
NASH is still partly unclear. In this 
thesis, a non-invasive NASH score was 
developed. It estimated population 
prevalence of 5% for NASH in Finnish 
adults. Furthermore, alterations in 
cholesterol metabolism, lipid oxidation 
and ketone body metabolism were 
revealed in those with NASH. This 
thesis highlights the significance of 
NASH and relates it with risk factors 
for other common diseases.
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